An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.
Tumors or cancer of the human BREAST.
In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.
Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Pathological processes of the BREAST.
A cell line derived from cultured tumor cells.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Tumors or cancer of the LIVER.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The nursing of an infant at the breast.
A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
A malignant epithelial tumor with a glandular organization.
Radiographic examination of the breast.
A common and benign breast disease characterized by varying degree of fibrocystic changes in the breast tissue. There are three major patterns of morphological changes, including FIBROSIS, formation of CYSTS, and proliferation of glandular tissue (adenosis). The fibrocystic breast has a dense irregular, lumpy, bumpy consistency.
Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.
Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The conic organs which usually give outlet to milk from the mammary glands.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Surgical procedure to remove one or both breasts.
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Tumors or cancer of the LUNG.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
DNA present in neoplastic tissue.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Removal of only enough breast tissue to ensure that the margins of the resected surgical specimen are free of tumor.
Tumors or cancer of the THYROID GLAND.
Tumors or cancer of the NASOPHARYNX.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)
Implants used to reconstruct and/or cosmetically enhance the female breast. They have an outer shell or envelope of silicone elastomer and are filled with either saline or silicone gel. The outer shell may be either smooth or textured.
An adenoma containing fibrous tissue. It should be differentiated from ADENOFIBROMA which is a tumor composed of connective tissue (fibroma) containing glandular (adeno-) structures. (From Dorland, 27th ed)
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.
The inspection of one's breasts, usually for signs of disease, especially neoplastic disease.
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Elements of limited time intervals, contributing to particular results or situations.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Glandular tissue in the BREAST of human that is under the influence of hormones such as ESTROGENS; PROGESTINS; and PROLACTIN. In WOMEN, after PARTURITION, the mammary glands secrete milk (MILK, HUMAN) for the nourishment of the young.
The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)
MAMMARY GLANDS in the non-human MAMMALS.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Use of ultrasound for imaging the breast. The most frequent application is the diagnosis of neoplasms of the female breast.
Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
Tumors or cancer of the COLON.
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human CHROMOSOME 17 at locus 17q21. Mutations of this gene are associated with the formation of HEREDITARY BREAST AND OVARIAN CANCER SYNDROME. It encodes a large nuclear protein that is a component of DNA repair pathways.
Tumors or cancer of the ESOPHAGUS.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)
Tumors or cancer of the MOUTH.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Cells that line the inner and outer surfaces of the body by forming cellular layers (EPITHELIUM) or masses. Epithelial cells lining the SKIN; the MOUTH; the NOSE; and the ANAL CANAL derive from ectoderm; those lining the RESPIRATORY SYSTEM and the DIGESTIVE SYSTEM derive from endoderm; others (CARDIOVASCULAR SYSTEM and LYMPHATIC SYSTEM) derive from mesoderm. Epithelial cells can be classified mainly by cell shape and function into squamous, glandular and transitional epithelial cells.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
RNA present in neoplastic tissue.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Tumors or cancer of the SKIN.
A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.
A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.
The erbB-2 gene is a proto-oncogene that codes for the erbB-2 receptor (RECEPTOR, ERBB-2), a protein with structural features similar to the epidermal growth factor receptor. Its name originates from the viral oncogene homolog (v-erbB) which is a truncated form of the chicken erbB gene found in the avian erythroblastosis virus. Overexpression and amplification of the gene is associated with a significant number of adenocarcinomas. The human c-erbB-2 gene is located at 17q21.2.
Tumors or cancer of the STOMACH.
A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)
Transplantation between animals of different species.
One of the ESTROGEN RECEPTORS that has marked affinity for ESTRADIOL. Its expression and function differs from, and in some ways opposes, ESTROGEN RECEPTOR BETA.
Tumors or cancer of the URINARY BLADDER.
Antibodies produced by a single clone of cells.
Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.
Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Area of the human body underneath the SHOULDER JOINT, also known as the armpit or underarm.
Tumors or cancer of the UTERINE CERVIX.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
The physiological period following the MENOPAUSE, the permanent cessation of the menstrual life.
A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Surgical reconstruction of the breast including both augmentation and reduction.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Any of the ducts which transport saliva. Salivary ducts include the parotid duct, the major and minor sublingual ducts, and the submandibular duct.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
Total mastectomy with axillary node dissection, but with preservation of the pectoral muscles.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.
A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.
The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.
Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.
Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.
A latent susceptibility to disease at the genetic level, which may be activated under certain conditions.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
A benign neoplasm composed of glandular and fibrous tissues, with a relatively large proportion of glands. (Stedman, 25th ed)
One or more layers of EPITHELIAL CELLS, supported by the basal lamina, which covers the inner or outer surfaces of the body.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
Large, branched, specialized sweat glands that empty into the upper portion of a HAIR FOLLICLE instead of directly onto the SKIN.
A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
A type II keratin that is found associated with the KERATIN-14 in the internal stratified EPITHELIUM. Mutations in the gene for keratin-5 are associated with EPIDERMOLYSIS BULLOSA SIMPLEX.
A fetal blood vessel connecting the pulmonary artery with the descending aorta.
The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
A type II keratin found associated with KERATIN-16 or KERATIN-17 in rapidly proliferating squamous epithelial tissue. Mutations in gene for keratin-6A and keratin-6B have been associated with PACHYONYCHIA CONGENITA, TYPE 1 and PACHYONYCHIA CONGENITA, TYPE 2 respectively.
An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
The period before MENOPAUSE. In premenopausal women, the climacteric transition from full sexual maturity to cessation of ovarian cycle takes place between the age of late thirty and early fifty.
A fluid-filled closed cavity or sac that is lined by an EPITHELIUM and found in the BREAST. It may appear as a single large cyst in one breast, multifocal, or bilateral in FIBROCYSTIC BREAST DISEASE.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The phosphoprotein encoded by the BRCA1 gene (GENE, BRCA1). In normal cells the BRCA1 protein is localized in the nucleus, whereas in the majority of breast cancer cell lines and in malignant pleural effusions from breast cancer patients, it is localized mainly in the cytoplasm. (Science 1995;270(5237):713,789-91)
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
An estrogen responsive cell line derived from a patient with metastatic human breast ADENOCARCINOMA (at the Michigan Cancer Foundation.)
A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.
Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.
Tumors or cancer of the gallbladder.
Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.
The washing of a body cavity or surface by flowing water or solution for therapy or diagnosis.
Tumors or cancer of the SALIVARY GLANDS.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Organized periodic procedures performed on large groups of people for the purpose of detecting disease.
A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.

Characterization of human MMTV-like (HML) elements similar to a sequence that was highly expressed in a human breast cancer: further definition of the HML-6 group. (1/2323)

Previously, we found a retroviral sequence, HML-6.2BC1, to be expressed at high levels in a multifocal ductal breast cancer from a 41-year-old woman who also developed ovarian carcinoma. The sequence of a human genomic clone (HML-6.28) selected by high-stringency hybridization with HML-6.2BC1 is reported here. It was 99% identical to HML-6.2BC1 and gave the same restriction fragments as total DNA. HML-6.28 is a 4.7-kb provirus with a 5'LTR, truncated in RT. Data from two similar genomic clones and sequences found in GenBank are also reported. Overlaps between them gave a rather complete picture of the HML-6.2BC1-like human endogenous retroviral elements. Work with somatic cell hybrids and FISH localized HML-6.28 to chromosome 6, band p21, close to the MHC region. The causal role of HML-6.28 in breast cancer remains unclear. Nevertheless, the ca. 20 Myr old HML-6 sequences enabled the definition of common and unique features of type A, B, and D (ABD) retroviruses. In Gag, HML-6 has no intervening sequences between matrix and capsid proteins, unlike extant exogenous ABD viruses, possibly an ancestral feature. Alignment of the dUTPase showed it to be present in all ABD viruses, but gave a phylogenetic tree different from trees made from other ABD genes, indicating a distinct phylogeny of dUTPase. A conserved 24-mer sequence in the amino terminus of some ABD envelope genes suggested a conserved function.  (+info)

Spectral morphometric characterization of breast carcinoma cells. (2/2323)

The spectral morphometric characteristics of standard haematoxylin and eosin breast carcinoma specimens were evaluated by light microscopy combined with a spectral imaging system. Light intensity at each wavelength in the range of 450-800 nm was recorded for 10(4) pixels from each field and represented as transmitted light spectra. A library of six characteristic spectra served to scan the cells and reconstruct new images depicting the nuclear area occupied by each spectrum. Fifteen cases of infiltrating ductal carcinoma and six cases of lobular carcinoma were examined; nine of the infiltrating ductal carcinoma and three of the lobular carcinoma showed an in situ component. The spectral morphometric analysis revealed a correlation between specific patterns of spectra and different groups of breast carcinoma cells. The most consistent result was that lobular carcinoma cells of in situ and infiltrating components from all patients showed a similar spectral pattern, whereas ductal carcinoma cells displayed spectral variety. Comparison of the in situ and the infiltrating ductal solid, cribriform and comedo carcinoma cells from the same patient revealed a strong similarity of the spectral elements and their relative distribution in the nucleus. The spectrum designated as number 5 in the library incorporated more than 40% of the nuclear area in 74.08% of the infiltrating lobular cells and in 13.64% of the infiltrating ductal carcinoma cells (P < 0.001). Spectrum number 2 appeared in all infiltrating ductal cells examined and in none of the lobular cells. These results indicate that spectrum number 5 is related to infiltrating lobular carcinoma, whereas spectrum number 2 is characteristic for infiltrating ductal carcinoma cells. Spectral similarity mapping of central necrotic regions of comedo type in situ carcinoma revealed nuclear fragmentation into defined segments composed of highly condensed chromatin. We conclude that the spectral morphometric features found for lobular and ductal cell populations may serve future automated histological diagnostics.  (+info)

Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. (3/2323)

We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperamplification, which leads to aberrant mitosis and chromosome instability. Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperamplification. Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperamplification is frequent in both tumor types. Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperamplification. However, in some cases, we observed centrosome hyperamplification in tumors that retained wild-type p53. These tumors contained high levels of Mdm2. Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperamplification. We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperamplification and chromosome instability in cultured cells.  (+info)

Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. (4/2323)

CD40 is present on B cells, monocytes, dendritic cells, and endothelial cells, as well as a variety of neoplastic cell types, including carcinomas. CD40 stimulation by an antibody has previously been demonstrated to induce activation-induced cell death in aggressive histology human B-cell lymphoma cell lines. Therefore, we wanted to assess the effects of a recombinant soluble human CD40 ligand (srhCD40L) on human breast carcinoma cell lines. Human breast carcinoma cell lines were examined for CD40 expression by flow cytometry. CD40 expression could be detected on several human breast cancer cell lines and this could be augmented with interferon-gamma. The cell lines were then incubated with a srhCD40L to assess effects on in vitro growth. srhCD40L significantly inhibited the proliferation of the CD40(+) human breast cancer cell lines. This inhibition could also be augmented with interferon-gamma. Viability was also affected and this was shown to be due to increased apoptosis of the cell lines in response to the ligand. Treatment of tumor-bearing mice was then performed to assess the in vivo efficacy of the ligand. Treatment of tumor-bearing SCID mice with the ligand resulted in significant increases in survival. Thus, CD40 stimulation by its ligand directly inhibits human breast carcinoma cells in vitro and in vivo. These results suggest that srhCD40L may be of clinical use to inhibit human breast carcinoma growth.  (+info)

Induction of mammary carcinomas by N-methyl-N-nitrosourea in ovariectomized rats treated with epidermal growth factor. (5/2323)

The importance of epidermal growth factor (EGF) in both normal and malignant mammary gland development are presented in these studies. Initial findings demonstrated that in the absence of ovarian hormones, EGF had a significant proliferative effect on mammary epithelial cells. To determine whether mammary epithelial cells grown with EGF, in the absence of ovarian hormones, could be transformed by N-methyl-N-nitrosourea (MNU), female ovariectomized Lewis rats were implanted with pellets containing EGF for 1 week and then treated with MNU for initiation. Two days after MNU treatment, ovaries were implanted and EGF pellets were removed from all ovariectomized groups in order to promote carcinogenesis. The mammary carcinoma incidence of the EGF-stimulated group (90%) was not significantly different from the intact group (100%). The mammary cancer morphology of EGF-treated carcinomas was either ductal carcinoma or cribriform adenocarcinoma, whereas intact animals developed mainly papillary and occasional cribriform carcinomas. Fifty-eight percent of the carcinomas from the EGF group were ovarian hormone-independent compared with 10% of carcinomas from the intact group. These results demonstrate that EGF-induced proliferation during initiation with MNU was sufficient to induce the transformation of mammary carcinomas in the absence of ovarian hormones. The hormonal dependency of these EGF-induced carcinomas were different compared with MNU-initiated mammary carcinomas in intact rats.  (+info)

Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. (6/2323)

A centrosomal serine/threonine kinase, AIK1(3)/breast tumor amplified kinase/aurora2, which was recently identified as an oncogene, shows high amino acid identity with chromosome segregation kinases, fly Aurora, and yeast Ipl1. Immunohistochemical analyses of invasive ductal adenocarcinomas of the breast revealed that overexpression of AIK1 was observed in 94% of the cases, irrespective of the histopathological type, whereas the protein was not detected in normal ductal and lobular cells. Benign breast lesions including fibrocystic disease and fibroadenoma (epithelial components) displayed weakly detectable AIK1 expression in part of the lesions. This is the first immunohistochemical report of AIK1 expression in primary human breast carcinomas. Although the physiological function(s) of AIK1 kinase during cell division remains to be determined, the markedly high positivity of AIK1 staining in the cancer lesions suggested a possible involvement of its overexpression in the tumorigenesis of some of breast cancer cells.  (+info)

The influence of margin width on local control of ductal carcinoma in situ of the breast. (7/2323)

BACKGROUND: Ductal carcinoma in situ is a non-invasive carcinoma that is unlikely to recur if completely excised. Margin width, the distance between the boundary of the lesion and the edge of the excised specimen, may be an important determinant of local recurrence. METHODS: Margin widths, determined by direct measurement or ocular micrometry, and standardized evaluation of the tumor for nuclear grade, comedonecrosis, and size were performed on 469 specimens of ductal carcinoma in situ from patients who had been treated with breast-conserving surgery with or without postoperative radiation therapy, according to the choice of the patient or her physician. We analyzed the results in relation to margin width and whether the patient received postoperative radiation therapy. RESULTS: The mean (+/-SE) estimated probability of recurrence at eight years was 0.04+/-0.02 among 133 patients whose excised lesions had margin widths of 10 mm or more in every direction. Among these patients there was no benefit from postoperative radiation therapy. There was also no statistically significant benefit from postoperative radiation therapy among patients with margin widths of 1 to <10 mm. In contrast, there was a statistically significant benefit from radiation among patients in whom margin widths were less than 1 mm. CONCLUSIONS: Postoperative radiation therapy did not lower the recurrence rate among patients with ductal carcinoma in situ that was excised with margins of 10 mm or more. Patients in whom the margin width is less than 1 mm can benefit from postoperative radiation therapy.  (+info)

Prospective sonographic study of 3093 breast tumors. (8/2323)

To evaluate the predictive ability of sonographic tumor characteristics to differentiate benign from malignant tumors, we examined 3093 breast tumors (2360 benign and 733 malignant tumors) with ultrasonography. The ratio of the longest dimension to the anteroposterior diameter of benign tumors was significantly larger than that of malignant tumors (1.88+/-0.1 versus 1.69+/-0.02, P < 0.0001). Shape, margins, echogenicity, internal echo pattern, retrotumor acoustic shadowing, compressibility, and microcalcification were significant factors in the logistic regression model. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of breast sonography for malignancy were 86.1, 66.1, 44.1, 93.9, and 70.8%, respectively. Biopsy of the tumor for pathologic diagnosis is recommended if sonographic features are suggestive of malignancy.  (+info)

There is accumulating evidence to suggest that different histological grades of invasive ductal breast carcinomas may have distinct molecular origins and pathogenesis and do not typically progress from one grade group to another (28, 29, 30, 31) . The different grades have different clinical behaviors, and within-grade studies to identify the more aggressive subgroups of these classes of breast tumors would be of great assistance in clinical management. The expression of basal/myoepithelial markers has been observed in a proportion of grade III invasive breast tumors, and the spectrum of basal-like tumors, also recognized by morphology (15 , 32) , molecular cytogenetics (16 , 33) , and expression profiling (18 , 19) , has been associated with poor prognosis (17) . CGH has the advantage of being applied to archival pathology specimens with long-term follow-up as well as being amenable to microdissection strategies to profile the molecular genetic change occurring in a pure population of tumor ...
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma tissue array with matched adjacent normal breast tissue, including TNM and pathology grade, 6 cases_24 cores, replacing BR243 \ BR243a for more molecular products just contact us
Gentaur molecular products has all kinds of products like :search , US Biomax \ Breast invasive ductal carcinoma with matched or unmatched adjacent normal breast tissue array, including TNM and pathology grade, 47cases_80cores, replacing BR802 \ BR802b for more molecular products just contact us
Jin, R.,Bay, B.H.,Chow, V.T.K.,Tan, P.H.,Lin, V.C.L. (2000). Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. British Journal of Cancer 83 (3) : 319-323. [email protected] Repository ...
Mas pin is a se rine p rotease inhibito r with tumo r-su p p resso r activity. Mas pin can su p p ress tumo r g rowth and metastasis in vivo and tumo r cell motility and invasion in vit ro. P revious
PURPOSE: Information on tubular carcinoma (TC) of breast is limited due to its rarity. A multi-institutional study was performed to investigate the prognosis and failure patterns of TC compared to invasive ductal carcinoma (IDC). MATERIALS AND METHODS: We collected retrospective data on 205 patients with TC from eleven institutions. For each TC case, 3 cases with IDC were matched according to similar size, t-stage, and n-stage from the same institution. Patterns of failure, disease free survival (DFS) and overall survival (OS) were assessed and compared between the groups. RESULTS: DFS at 5 years was 98.8% and 97.3% and OS at 5 years was 99.5% and 99.6% in TC and IDC, respectively. Among the patients with TC, 5 patients (2.4%) developed contralateral breast cancer, while 3 patients (0.5%) presented with contralateral breast cancer in patients with IDC. CONCLUSIONS: The TC of breast presents an excellent prognosis, but the contralateral breast cancer tends to be more frequently observed compared ...
We have lot of studies regarding Ductal Carcinoma in Situ (DCIS) succeeding into Invasive Ductal Carcinoma (IDC) of the breast. Still, there is hardly any study on the coexistence of both and its clinical significance.
Mai, K. T., Perkins, D. G. and Mirsky, D. (2003), Location and Extent of Positive Resection Margins and Ductal Carcinoma in Situ in Lumpectomy Specimens of Ductal Breast Carcinoma Examined with a Microscopic Three-Dimensional View. The Breast Journal, 9: 33-38. doi: 10.1046/j.1524-4741.2003.09108.x ...
New research from Amsterdam shows that women over the age of 50 who have been diagnosed with ductal carcinoma in situ have a higher chance of being alive ten years after their diagnosis than women in the general population, according to Science Daily. Ductal carcinoma in situ is considered a disease separate from breast cancer because it is at stage 0 and does not spread around the body. However, ductal carcinoma in situ can progress into full-blown breast cancer, which is why it is still treated with surgery or surgery in combination with radiation therapy.. The researcher Dr. Lotte Elshof presented findings at the European Cancer Congress 2017. Women who have been diagnosed with ductal carcinoma in situ should feel better about their future because of these findings, which show their longevity will not be impacted by this condition.. Dr. Jelle Wesseling and her team at the Netherlands Cancer Institute followed approximately 10,000 Dutch women with ductal carcinoma in situ between the years ...
Invasive ductal carcinoma (IDC) is the most common form of breast cancer. Find out about IDC symptoms, diagnosis and treatment at Breast Cancer Care.
approximately three-quarters of breast cancers Invasive ductal carcinoma - 55% of breast cancers Ductal carcinoma in situ - 13% Invasive lobular carcinoma - 5% The overall 5-year survival rate for both ... Ductal carcinoma in situ, on the other hand, is in itself harmless, although if untreated approximately 60% of these low grade DCIS lesions will become invasive over the course of 40 years in follow-up ...
Invasive ductal carcinoma is the most commonly diagnosed breast cancer and has a tendency to metastasize via lymphatics. This lesion, which accounts for 75% of breast cancers, has no specific histolog... more
Background: Mounting evidence indicates that tumor-specific host immunity is associated with favorable prognosis in a variety of cancer settings. However, the role of immunity in breast cancer remains controversial. The purpose of this study was to determine the significance of tumor infiltrating leukocytes (TIL) with respect to pathological features and patient survival in estrogen receptor alpha (ER) negative breast cancer.. Patients and Methods: Tissue microarrays and immunohistochemistry were used to assess and categorize TIL in a cohort of 255 ER-negative invasive ductal breast carcinomas. Cases were registered by the Manitoba Breast Tumor Bank during the years 1988 to 2000 and had a minimum follow-up of 36 months. Stromal and intraepithelial TIL expressing the markers CD3, CD8, CD4, TIA1, CD25, FOXP3, CD20, CD68, and myeloperoxidase (MPO) were quantified by an experienced pathologist (PHW) and evaluated for associations with pathological parameters and survival. The median value for each ...
IDC. A reproduction print of my original watercolor painting depicting invasive ductal carcinoma, the most common type of breast cancer. Healthy duct cells are shown progressing into cancerous cells as you move around the painting. The cancerous cells spill out as they become invasive, but encounter chemotherapeutic drugs which attack the cells inducing apoptosis ...
Hello, I was recently diagnozed with Invasive Ductal Carcinoma. I am 26 years old and this was such a shock to me and my husband. There are really no support groups in my area and I would love to hear from anyone going through this. ------------------------------------------------------------------------ This is an automatically-generated notice. If youd like to be removed from the mailing list, please visit the Medicine-On-Line Discussion Forum at ,http://www.meds.com/con_faq.html,, or send an email message to: [email protected] with the subject line blank and the body of the message containing the line: unsubscribe mol-cancer your-email-address where the phrase your-email-address is replaced with your actual email address ...
Purpose: The present study analyzed the polymorphisms of DNA repair genes and their impact on survival of patients with early breast cancer.Patients and methods: A total of 240 patients with surgically resected early invasive ductal breast cancer were enrolled in the present study, where patients who underwent neoadjuvant treatment were excluded. The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and thirteen single nucleotide polymorphisms of 12 DNA repair genes were determined using the Sequenom Mass array system.Results: Among the target SNPs, VARS2 rs2074511 and POLE rs5744857 were found to correlate with relapse-free survival (RFS) after curative surgery in the log-rank test. There was no difference in the clinical and tumor characteristics according to the genotypes of these two coding variants except for the higher incidence of positive ER in patients with the GG genotype of POLE rs5744857 (p = 0.025). Multivariate analysis showed that the GG genotype of ...
Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive carcinoma of the breast. Current prognostic markers based on histopathological examination are unable to accurately predict which DCIS cases will progress to invasive carcinoma or recur after surgical excision. Epigenetic changes have been shown to be a significant driver of tumorigenesis, and DNA methylation of specific gene promoters provides predictive and prognostic markers in many types of cancer, including invasive breast cancer. In general, the spectrum of genes that are methylated in DCIS strongly resembles that seen in invasive ductal carcinoma. The identification of specific prognostic markers in DCIS remains elusive and awaits additional work investigating a large panel of methylatable genes by using sensitive and reproducible technologies. This review critically appraises the role of methylation in DCIS and its use as a biomarker ...
TY - JOUR. T1 - Treatment of low-risk ductal carcinoma in situ. T2 - is nothing better than something?. AU - Benson, John R.. AU - Jatoi, Ismail. AU - Toi, Masakazu. PY - 2016/10/1. Y1 - 2016/10/1. N2 - The heterogeneous nature of ductal carcinoma in situ has been emphasised by data for breast-cancer screening that show substantial increases in the detection of early-stage non-invasive breast cancer but no noteworthy change in the incidence of invasive and distant metastatic disease. Indolent non-progressive forms of ductal carcinoma in situ are managed according to similar surgical strategies as high-risk disease, with extent of resection dictated by radiological and pathological estimates of tumour dimensions. Although adjuvant treatments might be withheld for low-risk lesions, surgical treatments incur potential morbidity, especially when mastectomy and breast reconstruction are done for widespread low-grade or intermediate-grade ductal carcinoma in situ. Low rates of deaths from breast ...
Ivanka Dimova, Whole Genome Microarray Analysis In Invasive Ductal Breast Cancer Revealed The Most Significant Changes Affect Chromosomes 1, 8, 17 And 20, International Journal of Sciences 01(2015):8- ...
Invasive ductal carcinoma is the most common type of breast malignancy, with varying molecular features and resistance to treatment. Although CD44+/CD24- cells are believed to act as breast cancer stem cells and to be linked to poor prognosis in some patients, the association between these cells and tumor recurrence or metastasis in all or some types of invasive ductal carcinoma is unclear. A total of 147 randomly selected primary and secondary invasive ductal carcinoma samples were assayed for expression of CD44, CD24, ER, PR, and Her2. The association between the proportions of CD44+/CD24- tumor cells and the clinico-pathological features of these patients was evaluated. CD44+/CD24- tumor cells were detected in 70.1% of the tumors, with a median proportion of 5.8%. The proportion of CD44+/CD24- tumor cells was significantly associated with lymph node involvement (P = 0.026) and PR status (P = 0.038), and was correlated with strong PR status in patients with recurrent or metastatic tumors (P = 0.046)
Symptoms, diagnosis, treatment and prognosis for invasive ductal carcinoma-from the Johns Hopkins Breast Center in Baltimore, MD. Also get info for medullary, mucinous, papillary and tubular ductal carcinomas.
Recent studies suggest an association between chronic inflammation, modulating the tissue microenvironment, and tumor biology. Tumor environment consists of tumor, stromal and endothelial cells and infiltrating macrophages, T lymphocytes, and dendritic cells, producing an array of cytokines, chemokines and growth factors, accounting for a complex cell interaction and regulation of differentiation, activation, function and survival of tumor and surrounding cells, responsible for tumor progression and spreading or induction of antitumor immune responses and rejection. Tumor Necrosis Factor (TNF) family members (19 ligands and 29 receptors) represent a pleiotropic family of agents, related to a plethora of cellular events from proliferation and differentiation to apoptosis and tumor reduction. Among these members, BAFF and APRIL (CD257 and CD256 respectively) gained an increased interest, in view of their role in cell protection, differentiation and growth, in a number of lymphocyte, epithelial and
Hollie Quinn suffered from the typical health complaints of an adult female; these included heartburn and acid reflux, along with painful cysts, vertigo and migraines.. Hollie says that she ate the typically American diet which was low in vegetables, high in sugar, and drank soda daily. She never questioned the health directives given to her by her doctors, and was never told that there might be a connection between her health issues and the diet that she was eating.. In 2002, when Hollie was just 27 years old and in her 38th week of pregnancy, she was diagnosed with an infiltrating ductal carcinoma. This is the most common type of breast cancer which affects some 80% of patients, and as its name suggests, the cancer had broken through the milk duct and was invading the surrounding tissues of the breast. Over time, invasive ductal carcinomas can spread to the lymph nodes and to other areas of the body. Hollies main tumor was 2.3 cm, with a second tumor measuring 0.6 cm. The larger tumor was a ...
Invasive (infiltrating) ductal carcinoma of the breast is a malignant epithelial tumor resulted from proliferation of ductal epithelium of breast - Atlas of Pathology
Fig. 1. A, Western blot analyses of STK15 expression in breast carcinoma cell line BT474 and in a near diploid nontumorigenesis breast epithelial cell line MCF10 using the rabbit polyclonal anti-STK15 antibody. The specificity of the antibody is reflected in the detection of a single protein band in the top panel, and the absence of any detectable band in the middle panel in which the antibody was preabsorbed by the peptide antigen against which the antibody was raised. The presence of similar intensity β-actin bands in the lanes in the bottom panel indicates comparable amounts of protein loading from the cell lysates. B, immunohistochemical assay of STK15 expression in the cell lines, using paraffin-embedded sections of cells reflecting high expression in the breast carcinoma cell line BT474 and very low expression in MCF10 cells.. ...
In conclusion, Dr. Lori Pierce, Vice Provost for Academic and Faculty Affairs and Professor of Radiation Oncology at the University of Michigan, says this article has summarized nicely the major challenges facing breast cancer patients and their physicians in the management of ductal carcinoma in situ (DCIS). DCIS is not an invasive disease but can progress to invasive breast cancer, and potentially impact survival, in a significant number of women if not adequately treated when diagnosed. And we know that for those patients treated with lumpectomy, radiation to follow will reduce the chance of DCIS returning and/or invasive disease developing by at least 50%. We also know, however, that in some patients, the likelihood that DCIS will progress to invasive disease is very low even in the absence of treatment. Unfortunately, we have not found a reproducible way to predict those who need to be treated and those who dont but many researchers are working on this very question. For now, clinicians ...
This report presents data that show that women who are diagnosed with ductal carcinoma in situ (DCIS) are at significantly increased risk of being diagnosed with invasive breast cancer later on in...
(KudoZ) English to Spanish translation of Metastatic Ductal Carcinoma of the Breast: carcinoma ductal metastásico de mama [Medical (general) (Medical)].
The most common type of invasive breast cancer. It begins in the lining of the milk ducts (thin tubes that carry milk from the lobules of the breast to the nipple) and spreads outside the ducts to surrounding normal tissue.
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether surgery is more effective with or without gefitinib in treating ductal carcinoma in situ.. PURPOSE: This randomized phase II trial is studying how well gefitinib together with surgery works compared to surgery alone for the treatment of women with ductal carcinoma in situ of the breast. ...
To compare the lesion distribution and the extent of the disease in ductal and lobular carcinomas of the breast, we studied 586 ductal and 133 lobular consecutive cancers. All cases were documented on large-format histology slides. The invasive component of ductal carcinomas was unifocal in 63.3% (371/586), multifocal in 35.5% (208/586), and diffuse in 1.2% (7/586) of the cases. The corresponding figures in the lobular group were 27.8% (37/133), 45.9% (61/586), and 26.3% (35/133), respectively. When the distribution of the in situ and invasive component in the same tumors was combined to give an aggregate pattern, the ductal carcinomas were unifocal in 41.6% (244/586), multifocal in 31.6% (185/586), and diffuse in 26.8% (157/586) of the cases. The corresponding figures in the lobular category were 15.0% (20/133), 54.2% (72/133), and 30.8% (41/133), respectively. Ductal cancers were extensive in 45.7% (268/586), lobular in 65.4% (87/133) of the cases. All these differences were statistically ...
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.). ***Please note that cell lines are not for sale and unavailable for purchase.***. Fill out our tumor models contact form to get started setting up your next preclinical study with us.. Histotype: Mammary/Breast. Tumor Line: Human. REF# 3846. ...
The distribution of ductal carcinoma in situ DCIS grade in 4232 women and its impact on overdiagnosis in breast cancer screening. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
On July 23, 2008, I was diagnosed with bilateral breast cancer, invasive ductal carcinoma, Stage II, and ductal carcinoma in situ, Stage O. This blog was started to keep my family and friends connected during my surgery and treatment. This is my story!. ...
On July 23, 2008, I was diagnosed with bilateral breast cancer, invasive ductal carcinoma, Stage II, and ductal carcinoma in situ, Stage O. This blog was started to keep my family and friends connected during my surgery and treatment. This is my story!. ...
Mammography screening is deemed cost-effective for women aged 50-70. Yet the utilities informing breast screening policy are limited in their ability to adequately capture the benefits and risks. The evaluation of many cancer screening programmes present results in terms of cost per QALY but fail to include any disutility for the patients who have been over-diagnosed and may receive unnecessary treatment. This thesis presents an overview of the challenges associated with valuing breast cancer states, using the results of an empirical study deriving utilities from 172 women in Melbourne, Australia as an example of potential methods to capture the disutility of overtreatment. Ductal carcinoma in situ was used as a proxy to quantify the benefits and harms associated with the sequelae of screening. Utilities derived from 172 women for health states explicitly describing overdiagnosis were lower than those from the literature, where it is unlikely that women were informed that their treatment may ...
Queenie - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: over 7 years ago, Female, Age: 74, Stage I
copland16 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 9 years ago, Female, Age: 48, Stage II, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
Rita - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 7 years ago, Female, Age: 50, Stage 0
penny364 - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: about 5 years ago, Female, Age: 71, Stage 0, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
fortysomething - Survivor: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Finished active treatment less than 5 years ago, Diagnosed: over 11 years ago, Female, Age: 50
djmandy - Patient: Breast Cancer > Ductal carcinoma in situ (DCIS) Patient Info: Prefer not to answer/not applicable/unsure, Diagnosed: almost 10 years ago, Female, Age: 50, Stage 0
Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Living with cancer as a chronic illness (undergoing adjuvant therapy), Diagnosed: almost 16 years ago, Female, Age: 53, Stage III, HER2 Positive: Yes, ER Positive: No, PR Positive: No
MarcieB - Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 3 years ago, Female, Age: 73, Stage II, HER2 Positive: Yes, ER Positive: Yes, PR Positive: Yes
Patient: Breast Cancer > Invasive (Infiltrating) Ductal Carcinoma Patient Info: Currently in active treatment (initial surgery, receiving chemo rounds/radiation), Diagnosed: almost 9 years ago, Female, Age: 66, Stage II, HER2 Positive: No, ER Positive: Yes, PR Positive: Yes
TY - JOUR. T1 - The immune microenvironment of breast ductal carcinoma in situ. AU - Thompson, Elizabeth. AU - Taube, Janis M.. AU - Elwood, Hillary. AU - Sharma, Rajni. AU - Meeker, Alan. AU - Warzecha, Hind Nassar. AU - Argani, Pedram. AU - Cimino-Mathews, Ashley. AU - Emens, Leisha A.. PY - 2016/3/1. Y1 - 2016/3/1. N2 - The host immune response has a key role in breast cancer progression and response to therapy. However, relative to primary invasive breast cancers, the immune milieu of breast ductal carcinoma in situ (DCIS) is less understood. Here, we profile tumor infiltrating lymphocytes and expression of the immune checkpoint ligand programmed death ligand 1 (PD-L1) in 27 cases of DCIS with known estrogen receptor (ER), progesterone receptor, and human epidermal growth factor 2 (HER-2) expression using tissue microarrays. Twenty-four cases were pure DCIS and three had associated invasive ductal carcinoma. Tumors were stained by immunohistochemistry for PD-L1, as well as the lymphocyte ...
Current clinicopathological parameters are useful predictors of breast ductal carcinoma in situ behaviour, but they are insufficient to define high risk patients for disease progression precisely. Thioredoxin interacting protein (TXNIP) is a key player of oxidative stress. This study aims to evaluate the role of TXNIP as a predictor of ductal carcinoma in situ progression. Tissue microarrays from 776 pure ductal carcinoma in situ and 239 mixed ductal carcinoma in situ and invasive tumors were constructed. All patients were treated at a single institution with a long-term follow-up and TXNIP expression was assessed using immunohistochemistry. TXNIP expression was investigated in terms of associations with clinicopathological and molecular features and patient outcome. Loss/reduced cytoplasmic expression of TXNIP was associated with features of aggressiveness including high nuclear grade (p=1.6x10-5), presence of comedo necrosis (p=0.001) and oestrogen receptor negative (ER-)/HER2- ductal ...
TY - JOUR. T1 - Sentinel lymph node identification in a primary ductal carcinoma arising in the vulva. AU - Martinez-Palones, J. M.. AU - Perez-Benavente, A.. AU - Diaz-Feijoo, B.. AU - Gil-Moreno, A.. AU - Roca, I.. AU - García-Jimenez, A.. AU - Aguilar-Martinez, I.. AU - Xercavins, J.. PY - 2007/3/1. Y1 - 2007/3/1. N2 - Primary or metastasic breast-like carcinoma of the vulva is a rare event. Because of the similarity with breast ductal carcinoma, we think that the same principles used for treatment of orthotopic breast cancer can be applied, as well as the use of sentinel lymph node technique, which is widely accepted in the management of early-stage breast cancer. We report a 49-old-year postmenopausal woman who was referred to our institution after small biopsy of a 3.5- × 3-cm right vulvar tumor. Histopathologically, infiltration of the vulvar dermis by a ductal carcinoma of mammary gland type was reported. At operation, the sentinel node technique revealed two sentinel nodes in the ...
Squamous cell carcinoma of the breast and its subtype, basal-human epidermal growth factor receptor 2 (HER2) phenotype, are very rare. Herein, we report a patient who developed recurrence of squamous cell carcinoma of the breast with basal-HER2 subtype 6 years after the initial diagnosis of invasive ductal carcinoma of the HER2 subtype. To the best of our knowledge, recurrence of invasive ductal carcinoma in the form of metaplastic squamous cell carcinoma of basal-HER2 subtype has not been reported previously. We present a pathological perspective of our experience ...
ConferenceSeries organizes Invasive Ductal Carcinoma national symposiums, conferences across the globe in association with popular Invasive Ductal Carcinoma associations and companies. OMICS group planned its conferences, and events in america, europe, middle east and asia pacific. locations which are popular with international conferences, symposiums and events are china, canada, dubai, uae, france, spain, india, australia, italy, germany, singapore, malaysia, brazil, south korea, san francisco, las vegas, san antonio, omaha, orlando, raleigh, santa clara, chicago, philadelphia, baltimore, united kingdom, valencia, dubai, beijing, hyderabad, bengaluru and mumbai
Gene expression profiling has taught us a great deal about the progression of fully-developed invasive breast cancer, and our study used this approach as a starting point to learn more about the progression of DCIS to invasive breast cancer. We are aware of at least 9 previous studies comparing expression between DCIS and invasive breast cancer, publishing results that can be compared with ours (8-16, 30). Collectively, these studies included 130 cases of DCIS and 126 of invasive breast cancer, which pales in comparison to previous expression profiling studies of invasive breast cancer alone involving thousands of cases. Our study increases the number of samples comparing DCIS to invasive breast cancer by about 50%, which is a helpful contribution given the relatively small numbers of cases overall addressing this important question.. A proportion of samples from this (17%) and the previous (37%) studies were paired DCIS and invasive breast cancer from the same breasts, which may not be the ...
AIMS--To determine if allelic loss on chromosomes 16q and 17p, commonly encountered in in situ and invasive ductal carcinomas, is present in atypical ductal hyperplasia (ADH); to determine whether ADH is a neoplastic (clonal) or hyperplastic (polyclonal) proliferation. METHODS--Fourteen cases of ADH were examined for allele loss at loci on chromosome 16q and 17p using a microdissection technique, polymorphic DNA markers and the polymerase chain reaction (PCR). RESULTS--Loss of heterozygosity (LOH) was detected in five of nine informative cases on chromosome 16q at the microsatellite D16S413 and two of eight informative cases on chromosome 17p at D17S796. CONCLUSIONS--The incidence of LOH at these loci is similar to that previously observed in ductal carcinoma in situ and in invasive ductal carcinoma. Because of the nature of the technique used, our findings also demonstrate that ADH is a monoclonal, and hence, neoplastic proliferation rather than a hyperplastic (polyclonal) condition as its name ...
Invasive lobular carcinoma (ILC), sometimes called infiltrating lobular carcinoma, is the second most common type of breast cancer after invasive ductal carcinoma. About 10% of all invasive breast cancers are invasive lobular carcinomas. Learn about the diagnosis and treatment of invasive lobular carcinoma.
Breastfeeding and Immunohistochemical Expression of ki-67, p53 and BCL2 in Infiltrating Lobular Breast Carcinoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Abstract: Background and Objectives: The initiating steps and precise pathway of breast tumorigenesis are poorly understood and it is unclear if Ductal Carcinoma In Situ (DCIS) progresses to invasive ductal carcinoma (IDCA) of the breast. This study was undertaken to identify proteins that are differentially expressed between IDCA and DCIS and that may predict the invasive potential of breast tumors. Methodology: It is utilized that the two-dimensional difference in gel electrophoresis technology (2D-DIGE) and tandem mass spectrometry (LC-MS/MS) to perform proteomic analysis of IDCA (MCF-7 and BT-474) and DCIS (HCC-1500 and HCC-38) cell lines. Results: Identified 10 proteins that were differentially expressed between IDCA and DCIS (≥2-fold difference; p≤0.05) and classified the proteins according to their Gene Ontology (GO). Out of these proteins, 60 kDa mitochondrial heat shock protein (HSPD1), Heat Shock Protein Beta 1 (HSPB1) and the voltage-dependent anion-selective channel protein 1 ...
Conducted in the three-county Seattle-Puget Sound metropolitan area, the population-based study included women ages 55 to 74 years: 880 of the women had invasive ductal breast cancer, 1,027 had invasive lobular breast cancer, and 856 of them had no cancer and served as the control group. Interviewing participants in person, researchers gathered in-depth histories of hypertension and heart disease, as well as risk factors for cancer, including family history, obesity, smoking, and alcohol use. Through a series of structured questions, the research also included detailed data regarding use of antihypertensive drugs, such as beginning and end dates of use, drug names, dose, route of administration, pattern of use, and indication ...
PHILADELPHIA - A recent report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, adds to the growing evidence that fish oil supplements may play a role in preventing chronic disease. Researchers at the Fred Hutchinson Cancer Research Center in Seattle, Wash., led by Emily White, Ph.D., a member of the public health sciences division, asked 35,016 postmenopausal women who did not have a history of breast cancer to complete a 24-page questionnaire about their use of non-vitamin, non-mineral specialty supplements in the Vitamins and Lifestyle (VITAL) cohort study. After six years of follow-up, 880 cases of breast cancer were identified using the Surveillance, Epidemiology and End Results registry. Regular use of fish oil supplements, which contain high levels of the omega-3 fatty acids, EPA and DHA, was linked with a 32 percent reduced risk of breast cancer. The reduction in risk appeared to be restricted to invasive ductal breast cancer, ...
The Y-box-binding protein 1 (YB-1), a member of the cold-shock domain RNA-and DNA-binding protein family, has pleiotropic functions such as regulation of the cell cycle. The aim of this study was to evaluate if YB-1 is a proliferative marker in breast cancer and elucidate potential downstream targets involved in YB-1-mediated cell cycle regulation using RNA interference technology. YB-1 protein expression was evaluated in tissue microarrays of 131 breast invasive ductal carcinomas by immunohistochemistry, while the YB-1 gene expression profile was evaluated in the T-47D, MDA-MB-231, ZR-75-1 and MCF7 breast cancer cell lines. Silencing of the YB-1 gene in T-47D breast cancer cells was performed using siRNA and the effects of down-regulation of YB-1 on cell growth and regulation of the cell cycle were ascertained. A focused panel of 84 genes involved in cell cycle progression was also examined. In tissue microarrays, YB-1 expression was shown to be associated with proliferating cell nuclear ...
Ductal carcinoma in situ is a noninvasive precancer condition. The treatment resembles the treatment of invasive breast cancer. The aim of this exploratory study was to gain knowledge on the level of postoperative pain, sensory disturbances, and distress among a small group of Danish women with ductal carcinoma in situ who had sentinel lymph node biopsy in order to plan a population study. A subgroup of patients with ductal carcinoma in situ (n = 20) was compared to patients with invasive breast cancer (n = 455) at time of diagnosis and after 12 months. Six patients were interviewed on the impact of the diagnosis and life after treatment. We found no significant difference in reported sensory disturbances or pain after 12 months between the groups. More than one-third (39%) of ductal carcinoma in situ patients reported moderate to severe distress (≥ 7 on the Distress Thermometer) at time of diagnosis decreasing to 10% after 12 months. Similarly 36% of breast cancer patients reported distress ...
BACKGROUND: To investigate markers for predicting breast cancer progression, we performed a candidate gene-based study that assessed expression change of three genes, cyclin D1, β-catenin, and metastasis-associated protein-1 (MTA1), involving in aggressive phenotypes of cancerous cells, namely hyperproliferation, epithelial-mesenchymal transition, and global transcriptional regulation.. METHODS: Specimens were from 150 enrolled female patients, with invasive ductal carcinoma, followed up for more than 10 years. mRNA expression of cyclin D1, β-catenin, and MTA1 in cancerous and noncancerous cells microdissected from the primary tumor site was determined by quantitative real-time PCR. The relationship between mRNA expression levels of the genes and clinicopathologic features was assessed by statistical analysis. Disease-free and overall survival (DFS and OS) were analyzed by Kaplan-Meier analysis with log-rank test and a multivariate Cox regression model.. RESULTS: Cyclin D1 was shown to be ...
Lobular breast cancer, or invasive lobular carcinoma, starts out in the lobules, the glands that produce milk. Learn about symptoms, treatments, and more.
Sirolimus in Preventing Invasive Breast Cancer in Patients with Ductal Carcinoma In Situ, Lobular Carcinoma In Situ, Atypical Lobular Hyperplasia, or Atypical Ductal Hyperplasia - NCT02642094
Abstract Ductal carcinoma in situ (DCIS) is an intraductal neoplastic proliferation of epithelial cells that is separated from the breast stroma by an intact layer of basement membrane and myoepithelial cells. DCIS is a non-obligate precursor of invasive breast cancer, and up to 40% of these lesions progress to invasive disease if untreated. Currently, it is not possible to predict accurately which DCIS would be more likely to progress to invasive breast cancer as neither the significant drivers of the invasive transition have been identified, nor has the clinical utility of tests predicting the likelihood of progression been demonstrated. Although molecular studies have shown that qualitatively, synchronous DCIS and invasive breast cancers are remarkably similar, there is burgeoning evidence to demonstrate that intra-tumor genetic heterogeneity is observed in a subset of DCIS, and that the process of progression to invasive disease may constitute an evolutionary bottleneck, resulting in the ...
Aimée was diagnosed with Stage 2B/3A Invasive Ductal Breast Cancer. She was selected as a pro-bono candidate for proton therapy and had a very successful run with it, totaling six weeks. She recently graduated on April 13, and received her medal of honor in the form of a challenge coin engraved with her patient number, 891. The coin signifies her fight against cancer, so she can put this chapter of her life behind her ...
TY - JOUR. T1 - Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. AU - Olsen, Lars Rønn. AU - Campos, Benito. AU - Winther, Ole. AU - Sgroi, Dennis C.. AU - Karger, Barry L.. AU - Brusic, Vladimir. PY - 2014/12/8. Y1 - 2014/12/8. N2 - Background: The majority of genetic biomarkers for human cancers are defined by statistical screening of high-throughput genomics data. While a large number of genetic biomarkers have been proposed for diagnostic and prognostic applications, only a small number have been applied in the clinic. Similarly, the use of proteomics methods for the discovery of cancer biomarkers is increasing. The emerging field of proteogenomics seeks to enrich the value of genomics and proteomics approaches by studying the intersection of genomics and proteomics data. This task is challenging due to the complex nature of transcriptional and translation regulatory mechanisms and the disparities between genomic and proteomic data from the same samples. In this ...
Aim of the study: Immunohistochemical evaluation of hormone receptors, Her2/neu, CK5/6, E-cadherin, beta-catenin, p53 and PTEN on Tissue Micro Array (TMA) of 46 Moroccan invasive breast carcinomas. Materials and Methods: The cases comprised 40 invasive ductal carcinomas, 4 invasive lobular carcinomas, 1 mixed carcinoma and 1 invasive colloid carcinoma. TMA paraffin blocs were prepared with the Beecher manual arrayer and immunostaining was performed using standard immunoperoxidase techniques. Results: 58.69% of the cases were ER positive. 43.18% (19/44) were triple negative breast cancers (TNBC) of which 15.78% (3/19) were of the basal phenotype expressing CK5/6. On the other hand, 72.22% (13/18) of the TNBC cases were IDC grade 3. Of the 18 IDC grade 3, 22.22% (4/18) were CK5/6 positive. 41.30% and 10.86% of the cases showed reduced expression of E-cadherin and beta-catenin respectively. Beta-catenin nuclear and cytoplasmic staining was noted in 20% and 97.82% respectively. p53 was overexpressed in 10
When a pathologist examines the tissue under a microscope, he or she looks for small clusters of tumor cells that appear to float in pools of mucin. The tumor may be made up mostly of mucin, or mostly of cancer cells separated by small amounts of mucin.. Mucinous carcinoma also can be found near, or mixed in with, other more common types of breast cancer. Sometimes a ductal carcinoma in situ (or DCIS, a cancer that has not spread outside the milk duct) is found near the mucinous carcinoma. A mucinous carcinoma also may have some areas within it that contain invasive ductal carcinoma cells. If the invasive ductal carcinoma cells make up more than 10% of the tumor, the cancer would be called a mixed mucinous carcinoma. A pure mucinous carcinoma means that at least 90-100% of the cells are mucinous.. Now or after surgery, the tissue should be tested for some other important features of a pure mucinous breast carcinoma:. ...
Our study found that a history of a clinical diagnosis of migraine is associated with a 26% reduced risk of breast cancer among both premenopausal and postmenopausal women. This result is consistent with the 33% reduction in risk of invasive ductal breast carcinomas observed in the only other published study to assess this relationship (1). In the data presented here, the association between migraine and breast cancer did not vary substantially by age at migraine diagnosis, but there was some suggestion that risks were lower among women who had used prescription migraine medications. Although we did not assess migraine severity, use of prescription medications may be a proxy for more severe disease, or this observation could also reflect a reduction in risk associated with use of these medications. The lack of a significant effect among women not using medication may also be the result of exposure misclassification because the proportion of women reporting a history of migraine who actually only ...
OS is a malignant tumor that occurs in bone tissues and mainly affects adolescents (16). Through developments in diagnostic and therapeutic techniques, the 5-year survival rate of patients with OS has increased by 60-70% in the last decade; however, the 20-year survival rate of patients with OS remains low, at ~20% (17,18). The mechanisms involved in the development of OS are largely unclear; thus, the identification of novel biomarkers in OS may be useful for future diagnosis and treatment of patients.. Dysregulated C-type lectins have been found in various diseases, including cancer (19,20). CLEC-2, a member of the C-type lectin family, was highly expressed in clear cell renal cell carcinoma and was positively associated with poor patient prognosis (21) and it was also observed to regulate cell proliferation and migration (22). CLEC3A, another C-type lectin, was reported to be highly expressed in breast invasive ductal carcinoma and promoted breast cancer cell proliferation and migration (8). ...
This is the first comprehensive study of MUC5AC immunoexpression in breast cancer. We detected MUC5AC expression in five of 68 cases, which included one pure colloid carcinoma (out of three cases) and four invasive ductal carcinomas (out of 65 cases). In a previous study, OConnell et al showed an altered pattern of mucin expression in mucinous (colloid) breast carcinomas.13 Using in situ hybridisation, these authors13 showed an increase of MUC2 and MUC5AC expression and a decrease of MUC1 expression in colloid breast carcinomas in comparison with non-colloid breast carcinomas. In the study of OConnell et al,13 MUC1 and MUC2 expression was studied by immunocytochemistry and in situ hybridisation, whereas the expression of MUC5AC was evaluated by in situ hybridisation alone. Our results reinforce their observations, showing that MUC5AC is overexpressed in some cases of colloid breast carcinoma. However, at variance with these authors13 we found that MUC5AC expression is not restricted to colloid ...
It is generally believed that atypical ductal hyperplasia (ADH) is a direct precursor of breast cancer and therefore portends breast cancer in the same breast, while atypical lobular hyperplasia (ALH) has an equal risk of cancer in both breasts and may not be a direct precursor of breast cancer. In the study, however, published in Cancer Prevention Research (2014;7;211-217) and led by Lynn C. Hartmann, MD, Professor of Oncology, cancer was twice as likely to occur in the breast having the biopsy, and this was true for both ADH and ALH.. Moreover, the findings run counter to current understanding that ALH primarily leads to lobular cancer. Instead, the researchers discovered that ALH was associated predominantly with later ductal cancers of the breast-also similar to cancers after ADH.. Both types resulted in invasive ductal cancers, and 69 percent were of intermediate or high grade. Further, about 25 percent had spread to the lymph nodes. Although the numbers were not statistically significant, ...
TY - JOUR. T1 - Should New No Ink On Tumor Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins. AU - Merrill, Andrea L.. AU - Tang, Rong. AU - Plichta, Jennifer K.. AU - Rai, Upahvan. AU - Coopey, Suzanne B.. AU - McEvoy, Maureen P.. AU - Hughes, Kevin S.. AU - Specht, Michelle C.. AU - Gadd, Michele A.. AU - Smith, Barbara L.. PY - 2016/10/1. Y1 - 2016/10/1. N2 - Background: No consensus exists for clear margins for breast-conserving surgery for pure ductal carcinoma in situ (DCIS). We examined the implications of applying a no ink on tumor standard for pure DCIS by correlating clear margin width with rates of residual disease. Methods: Lumpectomies with complete shaved cavity margins (SCMs) for pure DCIS at our institution from 2004 to 2007 were reviewed and patients with microinvasive cancer or multifocal disease requiring multiple wires excluded. Rates of residual disease in shaved margins were determined based on ...
TY - JOUR. T1 - Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. AU - Shamliyan, Tatyana. AU - Wang, Shi Yi. AU - Virnig, Beth A.. AU - Tuttle, Todd M.. AU - Kane, Robert L.. N1 - Copyright: Copyright 2012 Elsevier B.V., All rights reserved.. PY - 2010/10. Y1 - 2010/10. N2 - We synthesized the evidence of the association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ of the breast. We identified five randomized controlled clinical trials and 64 observational studies that were published in English from January 1970 to January 2009. Younger women with clinically presented ductal carcinoma in situ had higher risk of ipsilateral recurrent cancer. African Americans had higher mortality and greater rates of advanced recurrent cancer. Women with larger tumor size, comedo necrosis, worse pathological grading, positive surgical margins, and at a higher risk category, using a ...
Invasive Lobular Carcinoma or ILC, is the second most common form of breast cancer after invasive ductal carcinoma. It is invasive meaning that it can spread or invade into the surrounding breast tissue. ILC is usually (but not always) positive for the oestrogen receptor and the progesterone receptor. This cancer is commonly found in women…
E-cadherin local dynamics were studied in mature junctions, that is, junctions engaged in adhesion for many hours, in which cadherin expression level ...
E-cadherin local dynamics were studied in mature junctions, that is, junctions engaged in adhesion for many hours, in which cadherin expression level ...
This multicentre retrospective study is characterised by a long period of accrual (median follow-up: 136 months,; range: 16-292 months), which offers the advantage of providing interesting information about the trend of the disease. A certain number of patients (12 patients) enrolled in the first years have died during this long period of observation; other patients (47 patients) didnt return for the planned examination to the Centre of Radiotherapy where they had been treated, and were lost to follow-up. In addition only approximately 20% of patients were treated in the first period (from 1985 to 1990) and the number of cases increased progressively during the following years (Figure 1). Most of the cases belong to the two decades covered by the screening activity. Nevertheless, a large number of cases were also found in the younger age group, between 41 and 50. Increased debate and publicity about breast cancer screening after the introduction of screening programmes could have determined an ...
Ductal carcinoma in situ (DCIS) is an early form of a non-invasive breast cancer that begins as abnormal cells inside the milk ducts in the breast. It typically doesnt show signs or symptoms and its estimated that up to 40% of cases eventually become invasive if not treated.. The current standard treatment is to perform a lumpectomy or a mastectomy in more extreme cases. Clinical trials are underway to determine if some patients with ductal carcinoma in situ might be able to avoid surgery. In addition to considering proton therapy to target the cancer, Mayo Clinic is conducting a clinical trial that involves a vaccine that could boost immunity against the HER2 receptor, says Dr. Amy Degnim, a surgeon with the Mayo Clinic Cancer Center. HER2 is a protein that in some cases is on the outside of cancer cells and for women with ductal carcinoma in situ, these receptors are present in about 50% to 60% of the cases. In this Mayo Clinic Q&A podcast Dr. Degnim, and one of her patients, Helen ...
Description of disease Breast, infiltrating lobular carcinoma of the. Treatment Breast, infiltrating lobular carcinoma of the. Symptoms and causes Breast, infiltrating lobular carcinoma of the Prophylaxis Breast, infiltrating lobular carcinoma of the
Clinical trial for Pleomorphic Lobular Breast Carcinoma In Situ | Lobular Breast Carcinoma in Situ | LCIS | Lobular Carcinoma In Situ | Atypical Hyperplasia of the Breast , Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
TY - JOUR. T1 - Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance. AU - Yamaguchi, Mio. AU - Takagi, Kiyoshi. AU - Sato, Ai. AU - Miki, Yasuhiro. AU - Miyashita, Minoru. AU - Sasano, Hironobu. AU - Suzuki, Takashi. PY - 2020/9/1. Y1 - 2020/9/1. N2 - Background: RAS-related C3 botulinus toxin substrate 1 (Rac1) is a molecular switch fluctuating between GDP-bound inactive form (Rac1-GDP) and GTP-bound active form (Rac1-GTP) and involved in diverse function in both normal and malignant cells such as breast carcinoma cells. Although several studies have demonstrated immunolocalization of Rac1 protein in human breast carcinoma tissues, activation status of Rac1 still remains to be elucidated. Methods: We immunolocalized active form of Rac1 (Rac1-GTP) as well as total Rac1 using antibody specific for them in 115 invasive breast carcinoma tissues and correlated with clinicopathological parameters and clinical outcomes. Results: Rac1-GTP was ...
Hi. I did a search for Ductal Carcinoma and one of the hits was a letter from Jayna. I dont see anything else. Is there a web site I can go to? I would really like to find a lot more information about surgery, therapy and all alternatives. I know I am at the beginning of a long hard journey but I would like to give a little background which may help you point me in the right direction. I am 31 years old and back in August I found a lump. I spoke to my sister and a friend about it and both said wait a week or two to see if it would go away. I was a week away from my period so I waited. It did not go away. I called the OB/GYN and got an appointment for October 12th. I did not tell them about the lump, I guess I still figured it would go away. After I made the appointment I spoke to my mother, a breast cancer survivor twice. I told her the position of the lump and we both agreed that it was strange and would probably be nothing. Let me explain. My mother had breast cancer on the left side 11 years ...
Invasive lobular carcinoma has a much lower incidence than infiltrating ductal carcinoma, constituting less than 15% of cases of invasive breast cancer. It is characterized histologically by the &ldqu... more
Reducing cholesterol levels may inhibit breast cancer development, but the long-term use of cholesterol-lowering statin drugs is associated with more than double the risk of both types of breast cancer: invasive ductal carcinoma and invasive lobular carcinoma.
Background: Newer treatment modalities require subtyping of non-small cell lung carcinomas (NSCLC). Morphological differentiation is often difficult and various immunohistochemical (IHC) panels have been used to maximize the proportion of accurately subtyped NSCLC. Aim: The aim of this study was to subtype NSCLC on fine needle aspirates (FNA) using a minimal antibody panel. Materials and Methods: Cell blocks from 23 FNA samples with a morphological diagnosis of NSCLC were taken. IHC was evaluated (blinded to clinical data) for thyroid transcription factor-1 (TTF-1), cytokeratin (CK)7, CK20, and tumor protein p63. Results: TTF-1 was positive in 14 and negative in 9 cases. The p63 was positive in two cases each of TTF-1 positive and negative tumors. CK7 was positive in 12 of the 14 TTF-1 positive tumors and 4 of the TTF-1 negative tumors. CK20 was negative in all. All the 14 TTF-1 positive tumors were primary lung tumors, 12 being NSCLC and 2 being squamous cell carcinoma. Five of nine TTF-1 ...
The widespread adoption of screening mammography has led to an increase in the diagnosis of ductal carcinoma in situ (DCIS) of the breast. While it is estimated that 55,000 women in the US will be diagnosed with DCIS in 2013, only a small fraction of these women (~15%) will subsequently develop invasive breast cancer. However, most women with DCIS are treated as if they will develop invasive cancer. Almost a third of these women opt for a full mastectomy. In a majority of remaining women, the DCIS lesion is surgically excised with lumpectomy and, in over half of these women, additional radiation or tamoxifen treatment is provided. Thus, many women are receiving unnecessary adjuvant therapy to prevent invasive cancers that will not occur. Additionally, ~ 15% of women are not receiving adequate intervention because they will subsequently develop a subsequent invasive tumor even after receiving lumpectomy and adjuvant therapy. Identifying molecular markers that can accurately predict subsequent ...
TY - JOUR. T1 - A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. AU - Jakub, James W. AU - Murphy, Brittany L.. AU - Gonzalez, Alexandra B.. AU - Conners, Amy L.. AU - Henrichsen, Tara L.. AU - Maimone, Santo IV. AU - Keeney, Michael G.. AU - McLaughlin, Sarah A.. AU - Pockaj, Barbara A. AU - Chen, Beiyun. AU - Musonza, Tashinga. AU - Harmsen, William S.. AU - Boughey, Judy C. AU - Hieken, Tina J. AU - Habermann, Elizabeth B. AU - Shah, Harsh N.. AU - Degnim, Amy C. PY - 2017/8/1. Y1 - 2017/8/1. N2 - Background: Approximately 8-56% of patients with a core needle biopsy (CNB) diagnosis of ductal carcinoma in situ (DCIS) will be upstaged to invasive disease at the time of excision. Patients with invasive disease are recommended to undergo axillary nodal staging, most often requiring a second operation. We developed and validated a nomogram to preoperatively predict percentage of risk for upstaging to invasive cancer. Methods: We reviewed 834 cases of DCIS ...
Objective: This study investigated whether gene expression levels of key modulators of the oxysterol signalling pathway modify the prognosis of patients with oestrogen receptor-positive (ER+) breast carcinomas via interaction with endocrine therapy. Context: The prognosis of patients with ER+ breast carcinoma depends on several factors. Previous studies have suggested that some oxygenated forms of cholesterol (oxysterols) bind to oestrogen receptor and anti-oestrogen binding site which may deregulate cholesterol homoeostasis and influence effect of therapy. Design: The expression levels of 70 oxysterol pathway genes were evaluated in a test set of breast carcinomas differing in ER expression. The genes differentially expressed in ER+ tumours were assessed in a comprehensive set of ER+ tumours to evaluate their clinical significance. Patients: A total of 193 primary patients with breast carcinoma were included. Measurements: The transcript levels were determined by quantitative real-time ...
Find the best invasive breast cancer doctors in Bangalore. Get guidance from medical experts to select invasive breast cancer specialist in Bangalore from trusted hospitals - credihealth.com
FRIDAY, Oct. 25, 2019 (HealthDay News) - For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the Annals of Surgical Oncology.. William H. Ward, M.D., from Naval Medical Center in Portsmouth, Virginia, and colleagues used the National Cancer Database to identify women with a clinical diagnosis of DCIS between 2004 and 2014. Differences in overall survival (OS) and presence of invasion were compared for five intervals between diagnosis and surgery (≤30, 31 to 60, 61 to 90, 91 to 120, and 121 to 365 days).. The researchers identified 140,615 clinical DCIS patients, of whom 123,947 had pathologic diagnosis of DCIS and 16,668 had invasive ductal carcinoma. Overall, five-year OS was 95.8 percent, and unadjusted median delay from diagnosis to surgery was 38 days. There was a 7.4 percent increased relative risk for death for each ...
At Moffitt Cancer Center, breast cancer research is one of our primary areas of focus. Not only are we looking to determine how ductal carcinoma in situ develops, but also how it can be treated more effectively. For instance, we are studying various hormonal therapies and how they affect hormone receptor-positive cancers, using our laboratory advances to improve outcomes and quality of life for each of our patients.. Our expert oncologists can further explain the causes of ductal carcinoma in situ. To make an appointment, call 1-888-663-3488 or submit a new patient registration form online. No referral is required.. Helpful Links:. ...
After having a lumpectomy, chemo and radiation my wife is 2 1/2 years out from treatment and has a recurrence. She is scheduled for a mastectomy. What type of follow up treatment is availible? Her 1...
Since the introduction of the National Health Service Breast Screening Programme (NHSBSP), the number of ductal carcinoma in situ (DCIS) cases has increased considerably. Despite its increased incidence, some NHS leaflets and reports do not mention it, and the general public seems largely unaware of its existence. There are numerous biological studies dealing with this condition, but its psychosocial aspects seem to have been neglected. We have only been able to locate two British studies (Farmer, A. 1996. Unpublished PhD thesis, University of Southampton; Webb, C. and Koch, T. 1997. J. Adv. Nurs., 25, 154-525) that address some of the psychosocial issues associated with DCIS. This paper starts by defining DCIS and explaining its usual presentation, natural history and epidemiology. The treatment options for DCIS are described, together with the great deal of confusion and lack of agreement that accompanies them. The psychological issues that women with screen-detected DCIS have to deal with are ...
The research goal of the Sukumar laboratory is to obtain a molecular profile of breast cancer and to apply this knowledge to the early detection, diagnosis and therapy of breast cancer. Toward this end, SAGE, array, and proteomic analysis of breast carcinomas is being performed on noninvasive (ductal carcinoma in situ), invasive (invasive ductal carcinoma), and metastatic breast cancer (bone, ovarian, brain metastasis). The goal is to obtain mRNA and protein profiles of each cell type composing the lesion. This will help derive gene expression signatures typical for each stage of breast cancer for epithelial, stromal, and endothelial cells. By such careful analysis, candidate genes are identified, characterized and utilized for early detection and/or therapy of breast cancer.. Previous gene searches in breast cancer performed here identified a number of potential candidate tumor suppressors and oncogenes. These belonged to families of genes involved in a variety of functions in the cell. ...
"Infiltrating Ductal Carcinoma of the Breast (Carcinoma of No Special Type)". Stanford University School of Medicine. Archived ... For example, there is routinely a quantification of mitotic count in breast cancer classification. The mitoses must be counted ...
"The influence of margin width on local control of ductal carcinoma in situ of the breast". The New England Journal of Medicine ... "A prognostic index for ductal carcinoma in situ of the breast". Cancer. John Wiley & Sons. 77 (11): 2267-2274. doi:10.1002/( ... Lewinsky is a board-certified radiation oncologist who is among the top 15% of breast cancer researchers in terms of ... Lewinsky has published a number of medical papers in collaboration with several other scientists that focus on breast cancer. ...
... invasive ductal carcinoma, or other conditions. DCIS, or intraductal carcinoma, is by definition a breast cancer that is ... "Ductal Carcinoma In Situ (DCIS)". PubMed Health Glossary. DeSantis C, Siegel R, Bandi P, Jemal A (2011). "Breast cancer ... Clinical Breast Cancer. 6 (3): 216-22. doi:10.3816/cbc.2005.n.023. PMID 16137431. "Ductal carcinoma in situ". Getglue.com. ... of breast tissue, usually in the treatment of a malignant tumor or breast cancer. It is considered a viable breast conservation ...
Breast cancerEdit. Mastectomy specimen containing a very large cancer of the breast (in this case, an invasive ductal carcinoma ... Ductal carcinoma in situ (DCIS) breast cancerEdit. "DCIS patients and control subjects did not differ with respect to oral ... "What You Need To Know About Breast Cancer". National Cancer Institute.. *^ "Definite breast cancer risks". CancerHelp UK. ... Claus EB, Stowe M, Carter D (December 2001). "Breast carcinoma in situ: risk factors and screening patterns". Journal of the ...
... removed from her left breast. The eventual diagnosis was "ductal carcinoma with medullary features".[failed verification] Due ... Her memoir about breast cancer, My Breast: One Woman's Cancer Story (ISBN 0671017756; ISBN 978-0-671-01775-0) was originally a ... Wadler has been treated for both breast and ovarian cancer. In 1991, Wadler was diagnosed with breast cancer and had a ... Books My Breast: One Woman's Cancer Story Liaison: The True Story of the M. Butterfly Affair Wadler, Joyce (April 1992). "My ...
... lobular carcinoma in situ (LCIS) exhibits perinuclear staining with 34βE12. Ductal carcinoma in situ (DCIS) does not stain for ... Yeh IT, Mies C (March 2008). "Application of immunohistochemistry to breast lesions". Arch. Pathol. Lab. Med. 132 (3): 349-358 ... It can be used to differentiate in situ cancers of the breast; ...
"Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis". Journal of the National ... In 2015, she co-authored research into the use of 3D tissue culture models to study breast cancer cell generation and later ... This research had looked at wound cells in breast tissue, and identified 'repair cells' that could transform into a range of ... CS1 maint: discouraged parameter (link) Heaven, Douglas (13 March 2013). "Are breast milk stem cells the real deal for medicine ...
2011). "Role of RNA binding protein HuR in ductal carcinoma in situ of the breast". The Journal of Pathology. 224: 529-539. doi ...
In 2009, Bell Calloway was diagnosed with ductal carcinoma, an early stage of breast cancer. She underwent two lumpectomies, ... She subsequently underwent reconstructive surgery, in which tissue from her stomach was used to reconstruct her breast. She ... Vanessa Bell Calloway Shares Her Breast Cancer Survival Story". Ebony. Retrieved November 1, 2018.CS1 maint: multiple names: ...
Cartilage, cell nuclei (blue-purple), extracellular material (pink). Ductal carcinoma in situ (DCIS) in breast tissue, cell ... Basal cell carcinoma of the skin, cell nuclei (blue-purple), extracellular material (pink). Titford, M. (2005). "The long ...
"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland". Journal of ... produced by carcinoma cells, acts through paracrine signaling on endothelial cells and through autocrine signaling on carcinoma ... "Autocrine vascular endothelial growth factor signaling in breast cancer. Evidence from cell lines and primary breast cancer ... In HER2 overexpressing breast cancers, the HER2-IL-6-STAT3 signaling relationship could be targeted to develop new therapeutic ...
"Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type". The Journal of ... C11orf86 is down-regulated from non-neoplastic mucosa to adenomas and carcinomas, down-regulated in renal cell carcinoma, and ... and carcinomas". Experimental and Molecular Pathology. 90 (2): 201-9. doi:10.1016/j.yexmp.2010.12.004. PMID 21185829. Hidaka H ... aberrant expression and functional significance in renal cell carcinoma". Oncotarget. 3 (1): 44-57. doi:10.18632/oncotarget.417 ...
In 2015, Steckloff was diagnosed with invasive ductal carcinoma, the most common form of breast cancer. Due to the diagnosis, ...
... gamma-tubulin in atypical ductal hyperplasia and carcinoma of the breast". Cancer Science. 100 (4): 580-7. doi:10.1111/j.1349- ...
Many genes which are grouped into clusters show the same expression profiles in human invasive ductal breast carcinomas. ... Brain and breast related genes didn't cluster. This shows that at least some clusters consist of functionally related genes. ...
... can be used to differentiate lobular carcinoma of the breast from ductal carcinoma of the breast. CAM 5.2, an antibody that ... such as spindle cell carcinoma. It is considered useful in identifying microscopic metastases of breast carcinoma in lymph ... October 2004). "Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients ... 1997). "A two-dimensional gel database of human colon carcinoma proteins". Electrophoresis. 18 (3-4): 605-13. doi:10.1002/elps. ...
"Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast". Am. J ... of clear cell renal carcinomas. Two transcript variants encoding different isoforms have been identified for this gene. Loss of ... "Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau ...
... such as non-triple negative ductal carcinoma in situ, breast cancer, pancreatic adenocarcinoma, and colorectal carcinoma. It is ... Brown J (2016). Immunohistochemical and genomic analysis of ductal carcinoma in situ of the human breast (PDF) (Ph.D.). Kings ... Nisha K (March 2017). Early Genomic Events Associated with Dissemination of Breast Cancer Cells (Ph.D.). University of Toronto ...
State-of-the Science Conference on ductal carcinoma in situ; is a member of the early breast cancer clinical trialist group in ... McCaskill-Stevens co-directed the breast care and research center at the Indiana University Cancer Center. McCaskill-Stevens is ... the NCI Merit Award for breast cancer prevention; and listed on Ebony's 2013 Power 100 - Most Influential African Americans in ... and assumed responsibilities for breast cancer prevention with the community clinical oncology program (CCOP). She chaired the ...
"Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular ... elicits a humoral response in infiltrating ductal breast carcinomas: an immunoproteomics investigation". Clinical Biochemistry ... may lead to autoimmunity in breast cancer. As with breast cancer, upregulation of eEF1A expression is associated with prostate ... Shen R, Su ZZ, Olsson CA, Fisher PB (Jul 1995). "Identification of the human prostatic carcinoma oncogene PTI-1 by rapid ...
"Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular ... as has been observed for mRNA/protein levels of EEF1A1 in breast cancer. Coding regions are composed of codons, which are ... "Immune-related microRNAs are abundant in breast milk exosomes". International Journal of Biological Sciences. 8 (1): 118-123. ...
"Microdissection and SAGE as a combined tool to reveal gene expression in ductal carcinoma in situ of the breast". Mol. Carcinog ... 2006). "Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas". Mutat. Res. 594 (1-2): 78-85. doi ...
"Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma" (PDF). ... In a three dimensional model of breast ducts, reduced CSMD1 expression failed breast duct formation. Certain CSMD1 genetic ... It is a potential tumour suppressor, the deletion of which may result in head and neck carcinomas behaving more aggressively. ... CSMD1 protein expression was found to be reduced in patients with invasive breast cancer. Functional studies showed that CSMD1 ...
Invasive ductal carcinomas of the breast often have a scirrhous, stellate appearance caused by desmoplastic formations. ... Walker, Rosemary A (2001). "The complexities of breast cancer desmoplasia". Breast Cancer Research. 3 (3): 143-5. doi:10.1186/ ... malignant melanoma Desmoplastic squamous cell carcinoma Morpheaform basal cell carcinoma Microcystic adnexal carcinoma ... 2011). "Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs". Nature Medicine. 17 (7 ...
2010). "[Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas ... "Expression of FOXA1 and GATA-3 in breast cancer: The prognostic significance in hormone receptor-negative tumours". Breast ... FOXA1 in breast cancer is highly correlated with ERα+, GATA3+, and PR+ protein expression as well as endocrine signaling. FOXA1 ... 2009). "Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line". Biochem. Biophys. Res. Commun. 386 (1): 30 ...
The lump grew in the following two weeks, and she was diagnosed with invasive ductal carcinoma in June 2019. While her father ... Her U.S. college career was interrupted by a breast cancer diagnosis in 2019. The only daughter of Terei Mangakahia, a Māori ... Shortly after being named to the Opals' preliminary Olympic squad, Mangakahia discovered a lump on her left breast while ... finds new purpose during breast cancer battle". ESPN.com. Retrieved 21 February 2020. CS1 maint: discouraged parameter (link) " ...
Invasive ductal carcinoma: 55% of breast cancers Ductal carcinoma in situ: 13% Invasive lobular carcinoma: 5% The vast majority ... Thus invasive ductal carcinoma, the most common form of breast cancer, is adenocarcinoma but does not use the term in its name- ... "The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004". Cancer ... The adenoma, lacking the "carcinoma" attached to the end of it, suggests that it is a benign version of the malignant ...
The cells technically came from a triple-negative breast cancer, which was caused by an invasive ductal carcinoma in the ... Lasfargues, EY; Ozzello, L (1958). "Cultivation of human breast carcinomas". Journal of the National Cancer Institute. 21 (6): ... BT-20 is a breast cancer cell line derived from a 74-year-old human female in 1958 by E.Y. Lasfargues and L. Ozzello. ... The cells express an estrogen receptor with a deletion of exon 5, and are used in preclinical studies of breast cancer. ...
The cells were derived from the pleural effusion of a ductal carcinoma found in the mammary gland of an elderly human patient. ... T-47D is a human breast cancer cell line commonly used in biomedical research involving the hormonal expression of cancer cells ... T-47D cells are distinct from other human breast cancer cells in that their progesterone receptors are not regulated by ... T-47D cells have been employed in studies of the effects of progesterone on breast cancer and the corresponding transcriptional ...
7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships". Breast Cancer Res. 7 (2): R238-47. doi: ...
Breast cancer (invasive ductal). Over-expression. -. Immunohistochemistry. [12]. Breast cancer (BRCA1 deficient). Over- ... "Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas". Int. J. Cancer. 88 (1): 28-36. ... Breast cancer (progesteron receptor negative). Over-expression. -. messenger RNA. [16]. Breast cancer. Under-expression. 30%. ... Several alterations of the Rad51 gene have been associated with an increased risk of developing breast cancer. The breast ...
"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland". Journal of ... produced by carcinoma cells, acts through paracrine signaling on endothelial cells and through autocrine signaling on carcinoma ... "Autocrine vascular endothelial growth factor signaling in breast cancer. Evidence from cell lines and primary breast cancer ... In HER2 overexpressing breast cancers, the HER2-IL-6-STAT3 signaling relationship could be targeted to develop new therapeutic ...
"Contradictory mRNA and protein misexpression of EEF1A1 in ductal breast carcinoma due to cell cycle regulation and cellular ... as has been observed for mRNA/protein levels of EEF1A1 in breast cancer.[13] ... "Immune-related microRNAs are abundant in breast milk exosomes". International Journal of Biological Sciences. 8 (1): 118-23. ...
Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma. *Comedocarcinoma. *Paget's disease of the breast / ... The term 'crypt cell carcinoma' has been used for them, and though perhaps more accurate than considering them carcinoids, has ... "carcinoma-like", to describe the unique feature of behaving like a benign tumor despite having a malignant appearance ...
Ductal, lobular, and medullary. Ductal. *Ductal carcinoma in situ (DCIS): Paget's disease of the breast ... Inflammatory Breast Cancer Association. References[edit]. *^ "Inflammatory Breast Cancer: Questions and Answers". National ... Inflammatory breast cancer[1] is one of the most aggressive types of breast cancer that can occur in women of any age (and, ... "Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast ...
Breast: Nearly all breast cancers are ductal carcinoma.. *Prostate: The most common form of carcinoma of the prostate is ... In some types of carcinomas, Stage 0 carcinoma has been used to describe carcinoma in situ, and occult carcinomas detectable ... Some carcinomas are named for their or the putative cell of origin, (e.g.hepatocellular carcinoma, renal cell carcinoma). ... staging of breast carcinoma is more dependent on the size of the tumor, and in renal carcinoma, staging is based on both the ...
For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... An invasive ductal carcinoma of the breast (pale area at the center) surrounded by spikes of whitish scar tissue and yellow ... Radiation to the breast reduces the ability of that breast to produce milk and increases the risk of mastitis. Also, when ... for breast cancer, see Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. (February 2009). "Breast ...
Inactivation of CDH1 (accompany with loss of the wild-type allele) in 56% of lobular breast carcinomas.[54][55] ... When compared with invasive ductal carcinoma, E-cadherin expression is markedly reduced or absent in the great majority of ... Complete loss of E-cadherin protein expression in 84% of lobular breast carcinomas.[57] ... The authors also found that EMT can happen in breast cancer cell lines with hypermethylation of CDH1 promoter, but in breast ...
This mastectomy specimen contains an infiltrating ductal carcinoma of the breast. A pathologist will use immunohistochemistry ...
"Screening for Breast Cancer". U.S. Preventive Services Task Force. 2009.. *↑ Gøtzsche PC, Nielsen M (2011). Gøtzsche, Peter C ( ... A large invasive ductal carcinoma in a mastectomy specimen ପ୍ରତିଷେଧସମ୍ପାଦନ କରନ୍ତୁ. କର୍କଟ ସଙ୍କଟ କମ୍ କରିବା ନିମନ୍ତେ ନିଆଯାଉଥିବା ... NCCN Breast Cancer Clinical Practice Guidelines Panel (2009). "Breast cancer. Clinical practice guidelines in oncology". ... Thomsen A, Kolesar JM (December 2008). "Chemoprevention of breast cancer". Am J Health Syst Pharm. 65 (23): 2221-8. doi:10.2146 ...
Ductal. *Ductal carcinoma in situ (DCIS) *Paget's disease of the breast. *Comedocarcinoma ... In a woman who has not developed breast cancer, removing the breasts may reduce her risk of ever being diagnosed with breast ... Male breast cancer[edit]. Men with a BRCA mutation have a dramatically elevated relative risk of developing breast cancer, but ... BRCA-related breast cancer appears at an earlier age than sporadic breast cancer.[8]:89-111 It has been asserted that BRCA- ...
... of breast cancers), HER2+ (15%-30% of breast cancers), ER+/PR+ (about 70% of breast cancers), and Invasive lobular carcinoma ( ... BRCA1 expression is reduced or undetectable in the majority of high grade, ductal breast cancers.[61] It has long been noted ... BRCA1 promoter hypermethylation was present in only 13% of unselected primary breast carcinomas.[69] Similarly, BRCA1 promoter ... Mutation of BRCA1 in breast and ovarian cancerEdit. Only about 3%-8% of all women with breast cancer carry a mutation in BRCA1 ...
Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma. *Comedocarcinoma. *Paget's disease of the breast / ...
Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma. *Comedocarcinoma. *Paget's disease of the breast / ...
... specimen containing a very large cancer of the breast (in this case, an invasive ductal carcinoma) ... large areas of ductal carcinoma in situ or even those persons that are removing the breast because of the possibility of breast ... an invasive ductal carcinoma of the breast, pale area at the center ... A mastectomy is usually carried out to treat breast cancer[1]. In some cases, people believed to be at high risk of breast ...
Manual compression (quasistatic) elastography of invasive ductal carcinoma, a breast cancer.. Quasistatic elastography ( ... SSI is used for breast examination with a number of high-resolution linear transducers.[10] A large multi-center breast imaging ... In a breast self-examination, women look for hard lumps, as cancer is usually stiffer than healthy tissue. ... Shear wave elastography for breast masses is highly reproducible. Cosgrove DO, Berg WA, Doré CJ, Skyba DM, Henry JP, Gay J, ...
Ductal carcinoma(英语:Ductal carcinoma). *Mammary ductal carcinoma(英语:Mammary ductal carcinoma) ... Medullary carcinoma(英语:Medullary carcinoma). *Medullary carcinoma of the breast(英语:Medullary carcinoma of the breast) ... Lobular carcinoma(英语:Lobular carcinoma). *Lobular carcinoma in situ(英语:Lobular carcinoma in situ) ... 印戒细胞癌(Signet ring cell carcinoma,SRCC),又称黏液细胞癌(mucinous cell carcinoma,MCC)是
"IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland". Journal of ... "Breast Cancer Research. 9 (5): R63. doi:10.1186/bcr1769. PMC 2242658. PMID 17897439.. ... "Autocrine vascular endothelial growth factor signaling in breast cancer. Evidence from cell lines and primary breast cancer ... In breast cancer, the acquisition of tamoxifen resistance is another major therapeutic problem. It has been shown that ...
For example, the most common type of breast cancer is called ductal carcinoma of the breast. Here, the adjective ductal refers ... Nearly all cancers developing in the breast, prostate, lung, pancreas, and colon are carcinomas. ... spindle cell carcinoma, and small-cell carcinoma.[citation needed] ... Cancers are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ or ...
Se a comparamos co carcinoma ductal mamario invasivo, a expresión da E-cadherina está marcadamente reducida ou ausente na gran ... December 1997). "Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ ... "E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis". EMBO J. 14 (24): 6107- ... Inactivación de CDH1 (acompañada da perda do alelo de tipo silvestre) no 56% dos carcinomas de mama lobulares.[49][50] ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ... breast, and lung. Surgery may be performed on the pancreas in such cases, whether in hope of a cure or to alleviate symptoms.[ ... Other exocrine cancers include adenosquamous carcinomas, signet ring cell carcinomas, hepatoid carcinomas, colloid carcinomas, ... undifferentiated carcinomas, and undifferentiated carcinomas with osteoclast-like giant cells. Solid pseudopapillary tumor is a ...
Ductal carcinoma. *Mammary ductal carcinoma. *Pancreatic ductal carcinoma. *Comedocarcinoma. *Paget's disease of the breast / ... particularly breast and lung carcinoma.[1] It is not associated with H. pylori infection or chronic gastritis. The risk factors ... Microscopic appearance is signet ring cell carcinoma, which is tumor cells with mucin droplet that displaces the nucleus to one ...
... or the breast (ductal carcinoma in situ or lobular carcinoma in situ). ... Ductal carcinoma in situ of the breast is the most common precancer in women. ... Other forms require major surgery, the best known being intraductal carcinoma of the breast (also treated with radiotherapy). ... "Ductal carcinoma in situ: terminology, classification, and natural history". Journal of the National Cancer Institute. ...
For example, small, irregular, linear calcifications may be seen, via mammography, in a ductal carcinoma-in-situ to produce ... Breast diseaseEdit. In a number of breast pathologies, calcium is often deposited at sites of cell death or in association ...
... lung squamous cell carcinoma, kidney papillary carcinoma, clear cell kidney carcinoma, breast ductal carcinoma, renal cell ... thyroid carcinoma, bladder urothelial carcinoma - nonpapillary, uterine corpus (endometrial carcinoma), pancreatic ductal ... breast lobular carcinoma and lower grade glioma, esophageal carcinoma, ovarian serous cystadenocarcinoma, lung squamous cell ... rectal carcinoma, hepatocellular carcinoma, Head and neck (oral) squamous cell carcinoma, ...
"Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and ... "Measurement of steroid hormone receptors in breast cancer patients on tamoxifen". Breast Cancer Res. Treat. 26 (3): 237-46. doi ... 2007). "The genomic landscapes of human breast and colorectal cancers". Science. 318 (5853): 1108-1113. doi:10.1126/science. ... Selective estrogen receptor modulators (SERMs) are a commonly used adjuvant therapy in estrogen-receptor positive (ERα+) breast ...
... ang pinakakaraniwang uri ng kanser sa suso ay tinatawag na ductal carcinoma of the breast. Dito, ang pang-uring ductal ay ... Breast cancer BEACOPP Bleomycin, etoposide, Adriamycin (doxorubicin), cyclophosphamide, Oncovin (vincristine), procarbazine, ... Carcinoma: Ang mga kanser na hinango mula sa mga epithelial. Ang pangkat na ito ay kinabibilangan ng marami sa mga karaniwang ... Ang mga kanser ay karaniwang pinangalanan gamit ang -carcinoma, -sarcoma o -blastoma bilang isang hulapi na may salitang Latin ...
Composition of ductal epithelium two or more layers of cuboidal cells double layer of cuboidal cells [20]. ... the breast, abdomen, and forearm have 155 per cm2; and the back and legs have 60-80 per cm2.[2] ... Microcystic adnexal carcinoma. *Mucinous carcinoma. *Papillary eccrine adenoma. *Syringadenoma papilliferum. * ...
most breast cancers arise from the ductal epithelium (see ductal carcinoma in situ) ... phyllodes tumor and intraductal papilloma of the breast. *mastalgia is frequently caused by an imbalance of breast secretion in ... The majority of breast diseases either originate from lactiferous ducts or are closely related. The high susceptibility to ... most forms of fibrocystic breast changes and cysts are thought to originate from lactiferous ducts ...
Breast changes like atypical ductal hyperplasia[63] and lobular carcinoma in situ,[64][65][66] found in benign breast ... Mouse models of breast cancer metastasis. References[edit]. *^ a b c d e f g h i j k l m "Breast Cancer Treatment (PDQ®)". NCI ... Breast cancer is cancer that develops from breast tissue.[8] Signs of breast cancer may include a lump in the breast, a change ... "Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review". Breast cancer ...
Diseases : Breast Cancer, Breast Cancer: Ductal Carcinoma In Situ, Breast Cancer: MMTV-Associated, Ductal Carcinoma: Invasive ... Diseases : Breast Cancer, Breast Cancer: Ductal Carcinoma In Situ, Breast Cancer: MMTV-Associated, Ductal Carcinoma: Invasive ... Diseases : Breast Cancer, Breast Cancer: Ductal Carcinoma In Situ, Breast Cancer: Lobular Carcinoma in Situ (LCIS) ... Diseases : Breast Cancer, Breast Cancer: Ductal Carcinoma In Situ, Breast Cancer: Invasive Lobular Carcinoma (ILC) ...
recurrence invasive ductal carcinoma tmouse After having a lumpectomy, chemo and radiation my wife is 2 1/2 years out from ... 12 Ways to Cut Your Breast Cancer Risk Breast cancer is not an inevitability. From what you eat and drink to how much you ... 17 Deadly Rumors About Breast Cancer From mammograms to personal hygiene, learn the truth about these deadly breast cancer ... Dear tmouse, The treatment of recurrent breast cancer varies depending on where the cancer has recurred. The current standards ...
... and Ductal Carcinoma In Situ (DCIS) breast cancers are types that start in the milk ducts. Learn more about how they are ... How Is Ductal Carcinoma in Situ Treated? What Is Ductal Carcinoma?. Ductal carcinoma is a common type of breast cancer that ... What Is Invasive Ductal Carcinoma?. Invasive ductal carcinoma (IDC) accounts for about 80% of all invasive breast cancers in ... What is Ductal Carcinoma in Situ (DCIS)?. Ductal Carcinoma in Situ (DCIS), also known as intraductal carcinoma, accounts for ...
Ductal carcinoma in situ of the breast.. Burstein HJ1, Polyak K, Wong JS, Lester SC, Kaelin CM. ... Ductal carcinoma in situ of the breast. [N Engl J Med. 2004] ... Ductal carcinoma in situ of the breast. [N Engl J Med. 2004] ... Ductal carcinoma in situ of the breast. [N Engl J Med. 2004] ... Ductal carcinoma in situ of the breast. [N Engl J Med. 2004] ... Extramammary recurrence of DCIS after total mastectomy: an iatrogenic displacement following needling procedures? [Breast J. ...
Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast. *Ductal Breast Carcinoma In Situ ... 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ. *Ductal Breast ... Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen. *Breast Cancer ... or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer. *Ductal Breast Carcinoma ...
Also get info for medullary, mucinous, papillary and tubular ductal carcinomas. ... treatment and prognosis for invasive ductal carcinoma-from the Johns Hopkins Breast Center in Baltimore, MD. ... Invasive Ductal Carcinoma (IDC). Invasive ductal carcinoma (IDC), also known as infiltrating ductal carcinoma, is cancer that ... Mucinous Ductal Carcinoma - This occurs when cancer cells within the breast produce mucous, which also contains breast cancer ...
The pathology revealed grade 2-3 invasive ductal carcinoma of the right breast and ductal carcinoma in situ of the left breast ... High-grade ductal carcinoma in situ is incredibly rare in male patients. The prognosis for ductal carcinoma in situ (DCIS) in a ... Case Report: Ductal Carcinoma In Situ in the Male Breast. Joshua Chern, Lydia Liao, Raymond Baraldi, Elizabeth Tinney, Karen ... J. Armstrong, C. Saunders, and C. Metcalf, "Male breast ductal carcinoma in situ," ANZ Journal of Surgery, vol. 73, no. 9, pp. ...
Ductal carcinoma in situ (DCIS) of the breast is a noninvasive carcinoma with a wide spectrum of disease, ranging from low- ... E. B. Claus, M. Stowe, and D. Carter, "Oral contraceptives and the risk of ductal breast carcinoma in situ," Breast Cancer ... I. Jiveliouk, B. Corn, M. Inbar, and O. Merimsky, "Ductal carcinoma in situ of the breast in Israeli women treated by breast- ... "Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety," Breast, vol. 9, no. 1 ...
14 Studies found for: Breast Ductal Carcinoma , Antimitotic Agents. Also searched for Ductal breast carcinoma, Antimitotic ... Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1. *Invasive Ductal Breast Carcinoma ... Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer. *Breast ... Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women. *Tubular Breast Cancer ...
We review relevant publications on ductal carcinoma in situ of the breast in the past three years and we discuss pattern of ... We review relevant publications on ductal carcinoma in situ of the breast in the past three years and we discuss pattern of ... P. Gaye and A. Kassé, "Overview of Ductal Carcinoma in Situ of the Breast," Journal of Cancer Therapy, Vol. 5 No. 2, 2014, pp. ... "Ductal Carcinoma in Situ of the Breast," International Journal of Surgical Oncology, Vol. 2012, 2012, Article ID 123549. http ...
Prognostic classification of breast ductal carcinoma in situ. Lancet. 1995;345:1154-7.CrossRefPubMedGoogle Scholar ... Estrogen receptors in ductal carcinoma in situ of the breast. Am Surg. 1990;56:436-9.PubMedGoogle Scholar ... Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least 2 different lines of genetic evolution. J ... Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res. 2004;10:5160-7.CrossRefPubMedGoogle ...
... of the breast is the most common precursor to invasive carcinoma (IC), the second-leading cause of death in women in USA. There ... Ductal carcinoma in situ (DCIS) of the breast is the most common precursor to invasive carcinoma (IC), the second-leading cause ... Silverstein MJ (2000) Ductal carcinoma in situ of the breast. Annu Rev Med 51:17-32. doi:10.1146/annurev.med.51.1.17PubMed ... Invasive Breast Cancer Invasive Ductal Carcinoma Cellular Automaton Apoptotic Index Necrotic Core These keywords were added by ...
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ ... Tags: Bioinformatics, Breast Cancer, Breast Milk, Cancer, Carcinoma, Cell, DNA, DNA Sequencing, Ductal Carcinoma, Ductal ... Study provides insight into how early-stage breast cancer progresses to invasive ductal carcinoma. *Download PDF Copy ... A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) ...
PHILADELPHIA - Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in ... Six Factors May Predict Invasive Breast Cancer Recurrence after Ductal Carcinoma in Situ Diagnosis. ... Forty studies met the eligibility criteria of including at least ten invasive breast cancer events and at least one year of ... Finally, the researchers performed meta-analyses on all factors associated with the recurrence of invasive breast cancer ...
KEY WORDS: Breast neoplasms. p53 oncoprotein. c-erbB-2 oncoprotein. Hormonal receptors. Invasive ductal carcinoma of the breast ... Infiltrating ductal carcinomas of the breast with intense desmoplastic reaction (schirrous carcinoma) present overexpression of ... Schirrous invasive ductal carcinoma of the breast overexpress p53 oncoprotein Faculty of Medicine of Ribeirão Preto, ... 5. Hasebe T, Tsuda H, Hirohashi S, et al. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant ...
... * ... However, findings on an association between hormone use and ductal carcinoma in situ of the breast (DCIS), a possible precursor ... lesion of invasive breast cancer, are sparse and inconsistent. Womens Health Initiative data were used to assess the effects ... therapy with estrogen plus progestin is consistently reported to be associated with an increased risk of invasive breast cancer ...
... is the most common form of breast cancer. Find out about IDC symptoms, diagnosis and treatment at Breast Cancer Care. ... Invasive ductal breast cancer is the most common type of breast cancer in both women and men and accounts for about 75% of all ... We use the term invasive ductal breast cancer although this type of breast cancer is also known as: ... Try our new Breast Cancer Care app for moving forward after breast cancer ...
Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast.. Bohlke K1, Cramer DW, ... with risk of breast cancer in a study of 94 cases of premenopausal ductal carcinoma in situ and 76 controls. Compared with ... women in the upper two tertiles of IGF-I had an elevated risk for ductal carcinoma in situ. Conversely, compared with women in ... women in the upper two tertiles of IGFBP-3 had a decreased risk for ductal carcinoma in situ. After grouping women on the basis ...
Our work confirms the existence of distinct subpopulations of DCIS lesions, which will likely have utility in breast cancer ... micrographs of biomarkers whose expression correlates with breast cancer aggressiveness are divided by micrographs of ... Although epidemiological studies propose aggressive and non-aggressive forms of ductal carcinoma in situ (DCIS), they cannot be ... subpopulations of DCIS lesions with ratiometric properties resembling either benign fibroadenoma or invasive carcinoma samples ...
Metaplastic ductal carcinoma of the breast accounts for ,1% of all breast carcinomas. This case, which involved a predominant ... of all breast carcinomas.4. Clinically, metaplastic carcinoma has similar features to those of breast carcinoma in general.2,3, ... No suspicious contralateral breast lesion was identified.. Discussion. Metaplastic ductal carcinoma of the breast is a well- ... Radiological Case: Metaplastic ductal carcinoma of the breast. By David T. Boyd, MD, Pouneh Razavi, MD, Pedro Debrito, MD, ...
Forty-four cases were subclinical mammographically-detected carcinomas revealed by the clusters of m ... The role of axillary lymph node dissection for microinvasive ductal carcinoma in situ of the breast was analyzed in a series of ... Breast Neoplasms / pathology*, surgery. Carcinoma, Ductal, Breast / pathology*, surgery. Female. Humans. Lymph Node Excision*. ... The role of axillary lymph node dissection for microinvasive ductal carcinoma in situ of the breast was analyzed in a series of ...
Breast Ductal Carcinoma; Genomic DNA, Human reference standards from Cell lines. Available to purchase online at LGC Standards. ... HCC1395; Breast Ductal Carcinoma; Genomic DNA, Human. HCC1395; Breast Ductal Carcinoma; Genomic DNA, Human. ...
Buy Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer by Lisa A. Newman, Jessica M. Bensenhaver from ... Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer (Hardback). Lisa A. Newman (editor), Jessica M. Bensenhaver ... Written by experts in the field, Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer is a comprehensive, state- ... "This is a slim but meaty monograph on ductal carcinoma in situ (DCIS) and microinvasive breast cancer. ... The book is ...
Using Autopsy Series To Estimate the Disease "Reservoir" for Ductal Carcinoma in Situ of the Breast: How Much More Breast ... Using Autopsy Series To Estimate the Disease "Reservoir" for Ductal Carcinoma in Situ of the Breast: How Much More Breast ... Ductal Carcinoma in Situ of the Breast Rafael Fonseca, MD; Lynn C. Hartmann, MD; Ivy A. Petersen, MD; John H. Donohue, MD; ... Ductal Carcinoma in Situ of the Breast. Ann Intern Med. 1997;127:1013-1022. doi: 10.7326/0003-4819-127-11-199712010-00013 ...
Risk of recurrence after ductal carcinoma in situ of the breast.. L A Habel, J R Daling, P A Newcomb, S G Self, P L Porter, J L ... Risk of recurrence after ductal carcinoma in situ of the breast.. L A Habel, J R Daling, P A Newcomb, S G Self, P L Porter, J L ... Risk of recurrence after ductal carcinoma in situ of the breast.. L A Habel, J R Daling, P A Newcomb, S G Self, P L Porter, J L ... Risk of recurrence after ductal carcinoma in situ of the breast. Message Subject (Your Name) has forwarded a page to you from ...
... Am J Surg Pathol. 2011 Oct;35 ... A fibrotic focus diameter ,8 mm was a significant outcome predictor for UICC pTNM stages I and III invasive ductal carcinoma ... factors are very useful for accurately predicting the outcomes of patients with invasive ductal carcinoma of the breast. ... the histologic factors that accurately predict patient outcome among 1042 patients with invasive ductal carcinoma of the breast ...
... Breast. 2015 Dec;24(6):723-31 ... DOI: 10.1016/j.breast.2015.09.001 Abstract Background: Invasive micropapillary carcinoma (IMPC) of the breast and triple ... Keywords: Clinicopathologic characteristic; Invasive micropapillary carcinoma of breast; Prognosis; Triple negative breast ... Patients and methods: Retrospective analysis of 95 IMPC and 200 TNBC-IDC (invasive ductal carcinoma) was conducted to compare ...
Invasive ductal and lobular breast carcinomas are the most common malignancies of the breast, accounting for ∼80% and 15% of ... Differentiation of Lobular versus Ductal Breast Carcinomas by Expression Microarray Analysis James E. Korkola, Sandy DeVries, ... Differentiation of Lobular versus Ductal Breast Carcinomas by Expression Microarray Analysis James E. Korkola, Sandy DeVries, ... Differentiation of Lobular versus Ductal Breast Carcinomas by Expression Microarray Analysis James E. Korkola, Sandy DeVries, ...
Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation ... Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation ... Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation ... Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation ...
Location and Extent of Positive Resection Margins and Ductal Carcinoma in Situ in Lumpectomy Specimens of Ductal Breast ... and Extent of Positive Resection Margins and Ductal Carcinoma in Situ in Lumpectomy Specimens of Ductal Breast Carcinoma ... Department of Surgery, Queensway-Carleton Hospital and Womens Breast Health Center and University of Ottawa, Ottawa, Ontario, ... The Breast Journal, 9: 33-38. doi: 10.1046/j.1524-4741.2003.09108.x ...
  • 80-90% of the patients currently treated for DCIS present non-palpable breast lesions at diagnosis. (greenmedinfo.com)
  • Among women diagnosed with DCIS, risk of death from breast cancer was low, at least within the 10 years following diagnosis. (greenmedinfo.com)
  • We present a case of a male with unilateral invasive ductal carcinoma who was diagnosed with DCIS in the contralateral breast. (hindawi.com)
  • Ductal carcinoma in situ (DCIS) in males is exceedingly rare. (hindawi.com)
  • The lesions were found to be estrogen/progesterone receptor positive bilaterally, however, interestingly only the left breast DCIS was HER2 positive. (hindawi.com)
  • Our case is highly unusual in that the patient presented with invasive carcinoma and was discovered to have coexisting DCIS in the contralateral breast. (hindawi.com)
  • Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous neoplasm with invasive potential. (hindawi.com)
  • There are various classification systems used for DCIS, the most recent of which is based on the presence of intraepithelial neoplasia of the ductal epithelium (DIN). (hindawi.com)
  • Ductal carcinoma in situ (DCIS) of the breast is a noninvasive carcinoma with a wide spectrum of disease, ranging from low-grade to high-grade malignancy with foci of invasive malignancy. (hindawi.com)
  • Histologically, DCIS is characterized by a proliferation of malignant cells in the ductal epithelium that are confined to the basement membrane and are not invading the normal breast parenchyma. (hindawi.com)
  • Currently, DCIS accounts for 20-25% of all newly diagnosed cases of breast cancer [ 3 ] and 17-34% of mammographically detected breast neoplasms [ 4 , 5 ]. (hindawi.com)
  • A common type of carcinoma in situ called DCIS (ductal carcinoma in situ or intraductal carcinoma). (imaginis.com)
  • Ductal carcinoma in situ (or DCIS) refers to the most common type of noninvasive breast cancer in women. (imaginis.com)
  • With DCIS, the cancer cells are confined to milk ducts in the breast and have not spread into the fatty breast tissue or to any other part of the body (such as the lymph nodes). (imaginis.com)
  • DCIS is often first detected by a mammogram (an x-ray examination of soft breast tissues used to identify lumps, cysts, tumors, and other abnormalities). (imaginis.com)
  • Suspected DCIS is often confirmed by a breast biopsy in which a small sample of cells is removed for further examination under a microscope. (imaginis.com)
  • DCIS is a Stage 0 cancer, the earliest form of breast cancer. (imaginis.com)
  • The term, ductal carcinoma in situ (DCIS), refers to a family of cancers that occur in the breast ducts. (imaginis.com)
  • Solid DCIS: cancer cells completely fill the affected breast ducts. (imaginis.com)
  • Pathologists are able to easily distinguish between comedo type DCIS and other non-comedo types when examining the cells under a microscope because comedo type DCIS tends to plug the center of the breast ducts with necrosis (dead cells). (imaginis.com)
  • DCIS patients with multiple areas of cancer within the breast are often encouraged to choose a mastectomy. (imaginis.com)
  • Physicians do not typically remove the axillary (underarm) lymph nodes in DCIS patients because the cancer is usually confined to the breast ducts. (imaginis.com)
  • Ductal carcinoma in situ (DCIS) of the breast is the most common precursor to invasive carcinoma (IC), the second-leading cause of death in women in USA. (springer.com)
  • A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center. (news-medical.net)
  • The study provides new insight into how DCIS leads to invasive ductal carcinoma (IDC), and provides a clearer understanding of why some of these cancers go undetected. (news-medical.net)
  • While DCIS is the most common form of early-stage breast cancer and is often detected during mammography, 10 to 30 percent of this type of cancer progresses to IDC,' said Nicholas Navin, Ph.D., associate professor of Genetics. (news-medical.net)
  • PHILADELPHIA - Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to data from a meta-analysis published in Cancer Epidemiology, Biomarkers & Prevention , a journal of the American Association for Cancer Research. (aacr.org)
  • There is a large unmet need to distinguish harmless from potentially hazardous DCIS," said senior author of the study Jelle Wesseling, MD, PhD , professor of breast pathology in the divisions of diagnostic oncology and molecular pathology at the Netherlands Cancer Institute and Leiden University Medical Center. (aacr.org)
  • Wesseling, lead author and PhD student Lindy Visser, and colleagues performed a systematic review of 1,781 studies from the PubMed database from 1970 to June 2018 to assess the risk of ipsilateral (same side) invasive breast cancer recurrence in women primarily diagnosed and treated for DCIS. (aacr.org)
  • However, findings on an association between hormone use and ductal carcinoma in situ of the breast (DCIS), a possible precursor lesion of invasive breast cancer, are sparse and inconsistent. (healthpartners.com)
  • Although epidemiological studies propose aggressive and non-aggressive forms of ductal carcinoma in situ (DCIS), they cannot be identified with conventional histopathology. (nature.com)
  • BRIM identified subpopulations of DCIS lesions with ratiometric properties resembling either benign fibroadenoma or invasive carcinoma samples. (nature.com)
  • Our work confirms the existence of distinct subpopulations of DCIS lesions, which will likely have utility in breast cancer research and clinical practice. (nature.com)
  • Ductal carcinoma in situ (DCIS) of the breast is the most common type of non-invasive breast cancer. (nature.com)
  • Although it is believed that DCIS lesions become invasive breast cancer, this has not been proven, nor has the fraction of DCIS cases progressing to invasive cancer been established. (nature.com)
  • Several of the challenging and clinically-relevant scenarios of DCIS that appear in daily practice is discussed, including the difficulties of distinguishing "true" DCIS from borderline patterns of other breast diseases and the therapeutic implications of differentiating these various diagnoses. (waterstones.com)
  • The text also explores the data regarding DCIS in medical research in hereditary susceptibility for breast cancer and race/ethnicity-associated disparities in breast cancer. (waterstones.com)
  • This is a slim but meaty monograph on ductal carcinoma in situ (DCIS) and microinvasive breast cancer. (waterstones.com)
  • The increasing incidence and biological heterogeneity of ductal carcinoma in situ (DCIS) of the breast have made the management of this entity challenging and controversial. (annals.org)
  • No data from randomized trials compare mastectomy and breast-conserving therapy for the treatment of DCIS. (annals.org)
  • With more refined molecular analysis, the relation of DCIS to invasive breast cancer will be better defined. (annals.org)
  • Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. (knowcancer.com)
  • Ductal carcinoma in situ (DCIS) is breast cancer, but it is non-invasive (stage 0). (komen.org)
  • Although DCIS is not invasive breast cancer, it can sometimes turn into invasive breast cancer. (komen.org)
  • About half the time, it returns as DCIS and about half the time it returns as invasive breast cancer. (komen.org)
  • Treatment for DCIS is similar to treatment for invasive breast cancer. (komen.org)
  • For women who have the option, lumpectomy plus radiation therapy and mastectomy are equally effective in lowering the risk of invasive breast cancer and DCIS recurrence . (komen.org)
  • Although aromatase inhibitors are used to treat estrogen receptor-positive invasive breast cancer, data on their use in treating DCIS are limited. (komen.org)
  • These women have an excellent prognosis with a low risk of invasive breast cancer or DCIS recurrence, so the benefit of tamoxifen is likely very small. (komen.org)
  • Among women with the same treatments for DCIS, race and ethnicity do not seem to impact rates of DCIS recurrence or invasive breast cancer. (komen.org)
  • The good news is that most DCIS will not progress to invasive breast cancer. (komen.org)
  • 11 However, health care providers cannot yet predict which cases of DCIS will turn into invasive breast cancer and which will not. (komen.org)
  • They get little benefit (beyond peace of mind) from treatment because they would never develop invasive breast cancer with or without treatment for DCIS. (komen.org)
  • Ductal carcinoma in situ (DCIS) of the breast is an early, localized cluster of cancer cells that start in the milk passages (ducts) but have not penetrated the duct walls into the surrounding tissue. (medifocus.com)
  • By definition, DCIS is a non-invasive form of breast cancer because the cancer cells are confined to the milk ducts of the breast. (medifocus.com)
  • Although, by definition, DCIS is a non-invasive form of breast cancer, if left untreated, it may progress to 'true' breast cancer by spreading into and invading the surrounding healthy breast tissue. (medifocus.com)
  • Because doctors cannot predict with any degree of certainty whether DCIS will develop into invasive breast cancer, early diagnosis and treatment is crucial. (medifocus.com)
  • Because DCIS is a "forerunner" of invasive breast cancer, early diagnosis and treatment are crucial for reducing the risk of developing invasive breast cancer. (medifocus.com)
  • That's why we created the Medifocus Guidebook on Ductal Carcinoma in Situ of the Breast , a comprehensive 188 page patient Guidebook that contains vital information about DCIS that you won't find anywhere in a single source. (medifocus.com)
  • The relationship between DCIS and other adenocarcinomas of the breast, such as lobular carcinoma in situ (LCIS). (medifocus.com)
  • The role of nuclear grade and specific genetic mutations , such as mutation of the p53 gene, in predicting the likelihood of DCIS developing into invasive breast cancer. (medifocus.com)
  • The signs and symptoms of DCIS and other forms of breast cancer. (medifocus.com)
  • Prevent DCIS from developing into invasive breast cancer. (medifocus.com)
  • I. Reduction of mammary stem/progenitor cells (MaSC) in ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), atypical lobular hyperplasia (ALH) or atypical ductal hyperplasia (ADH) in patients receiving sirolimus (rapamycin). (cancer.gov)
  • I. To demonstrate that 2 mg once daily per breast of 4-hydroxytamoxifen (4-OHT) topical gel results in a reduction in the Ki-67 labeling index of ductal breast carcinoma in situ (DCIS) lesions that is not inferior to that seen with 20 mg daily oral tamoxifen citrate (TAM) for 4-10 weeks, when comparing the base-line diagnostic core biopsy to the therapeutic surgical excision sample. (clinicaltrials.gov)
  • Purpose: To assess the cosmetic impact of breast conserving surgery (BCS), whole breast irradiation (WBI) fractionation and tumour bed boost (TBB) use in a phase III trial for women with ductal carcinoma in situ (DCIS) of the breast. (rug.nl)
  • Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy. (medifocus.com)
  • There is controversy and confusion regarding therapy for patients with ductal carcinoma in situ (DCIS) of the breast. (uni-bonn.de)
  • Three hundred thirty-three patients with pure DCIS treated with breast preservation (195 by excision only and 138 by excision plus radiation therapy) were studied with detection of local recurrence as the end point. (uni-bonn.de)
  • PURPOSE: Local recurrence is a major concern in patients who have undergone surgery for ductal carcinoma in situ (DCIS). (koreamed.org)
  • Background: Risk of invasive cancer following treatment for ductal carcinoma in situ (DCIS) is associated with both treatment- and tumor-related factors. (aacrjournals.org)
  • We investigated whether breast density is an independent predictor of subsequent breast events among women treated for DCIS. (aacrjournals.org)
  • Population: A prospective cohort study of 3,274 women ages 30 to 93 in the Breast Cancer Surveillance Consortium treated with lumpectomy for DCIS between 1993 and 2005. (aacrjournals.org)
  • Methods: Ipsilateral and contralateral breast cancer following lumpectomy for DCIS were ascertained through state tumor registries, regional Surveillance Epidemiology and End Results program or pathology databases. (aacrjournals.org)
  • Conclusion: High breast density is associated with contralateral, but not ipsilateral, invasive breast cancer following lumpectomy for DCIS. (aacrjournals.org)
  • Thus, women with DCIS and high breast density may especially benefit from antiestrogenic therapy to reduce the risk of contralateral invasive disease. (aacrjournals.org)
  • However, histologic and genomic studies support a potential precursor role of DCIS for some invasive breast cancers ( 4 - 6 ). (aacrjournals.org)
  • Accordingly, DCIS is treated aggressively in an effort to prevent subsequent invasive breast cancer. (aacrjournals.org)
  • However, even with biopsy alone, not all DCIS will be associated with a subsequent invasive breast cancer ( 9 - 11 ). (aacrjournals.org)
  • Nevertheless, even among women selected to have the lowest risk DCIS lesions, lumpectomy alone is associated with a 0.5% to 2% annual risk of subsequent tumor events, almost half of which are invasive breast cancer ( 10 , 12 , 15 , 16 ). (aacrjournals.org)
  • Little is known about whether modifiable risk factors for breast cancer progression from DCIS to invasive cancer exist. (aacrjournals.org)
  • In 2016, breast cancer incidence in the United States was of 231,840 cases, and 60,290 (21.7%) were diagnosed as ductal carcinoma in situ (DCIS). (scielo.br)
  • It is noteworthy that, when left untreated, DCIS poses a risk between 30 and 50% of progressing to invasive carcinoma within 10 years. (scielo.br)
  • There is evidence that the activity mentioned is significantly more marked in DCIS lesions than in invasive carcinoma. (scielo.br)
  • Observed prevalence of occult invasive breast cancer or ductal carcinoma in situ (DCIS) in which the number of women who were given a diagnosis was the numerator and the number of women examined was the denominator. (annals.org)
  • The S100A7 (psoriasin) gene is highly expressed in ductal carcinoma in situ (DCIS) of the breast and can be downregulated in invasive carcinoma. (sigmaaldrich.com)
  • In order to investigate the relationship between S100A7 and progression from DCIS to invasive carcinoma, we studied S100A7 expression in 136 patients with DCIS (including 46 patients with associated invasive carcinoma) by immunohistochemistry. (sigmaaldrich.com)
  • S100A7 status was no different between DCIS with and DCIS without an invasive component, but higher levels of S100A7 were present in DCIS associated with invasive carcinoma (P (sigmaaldrich.com)
  • The findings reported here suggest that, although S100A7 may not be a marker for recurrence of DCIS, it is associated with poor prognostic markers in DCIS and may influence progression of breast carcinoma through its interaction with and influence on Jab1. (sigmaaldrich.com)
  • The identification of markers associated with progression to invasive breast cancer (IBC) is a major factor that can guide physicians in the initial therapeutic decision and the management of ductal carcinoma in situ (DCIS). (aacrjournals.org)
  • In contrast to the dramatic improvement in our ability to detect ductal carcinoma in situ (DCIS), our understanding of the pathophysiology of this disease and the factors involved in its progression to invasive breast carcinoma (IBC) is limited ( 1 ). (aacrjournals.org)
  • The initiating steps and precise pathway of breast tumorigenesis are poorly understood and it is unclear if Ductal Carcinoma In Situ (DCIS) progresses to invasive ductal carcinoma (IDCA) of the breast. (scialert.net)
  • This study was undertaken to identify proteins that are differentially expressed between IDCA and DCIS and that may predict the invasive potential of breast tumors. (scialert.net)
  • Several models have been described as potential mechanisms for the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer (IBC). (springer.com)
  • Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer (IBC). (springer.com)
  • Regarding the in situ component, the DCIS grade was in all cases concordant with the grade of the invasive carcinoma. (springer.com)
  • Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? (medworm.com)
  • Mittal Miller The mechanisms that drive ductal carcinoma in situ (DCIS) progression to invasive cancer are not clear. (medworm.com)
  • MRI use was not consistently different between women diagnosed with DCIS and with locally invasive breast cancer. (ahrq.gov)
  • In the same year, approximately 63,300 women were diagnosed with ductal carcinoma in situ (DCIS) of the breast. (ahrq.gov)
  • DCIS is noninvasive breast cancer representing a wide variety of cell abnormalities confined to the ducts of the breast. (ahrq.gov)
  • DCIS has been implicated as a precursor to invasive breast cancer. (ahrq.gov)
  • While we do not know the percentage of cases of DCIS that would progress to invasive breast cancer, studies suggest a very high risk of invasive breast cancer among women diagnosed with DCIS. (ahrq.gov)
  • Therefore, optimal management of DCIS to prevent subsequent invasive breast cancer is of strong clinical interest. (ahrq.gov)
  • The typical treatment for both DCIS and early invasive breast cancer is surgical removal of the tumor by mastectomy or breast- conserving surgery (BCS) plus radiation therapy, and use of MRI may influence treatment planning.6 For some patients, mammography can underestimate the extent of DCIS and invasive cancer. (ahrq.gov)
  • Our study describes the use of preoperative MRI among older women with DCIS and early invasive breast cancer. (ahrq.gov)
  • This report presents data that show that women who are diagnosed with ductal carcinoma in situ (DCIS) are at significantly increased risk of being diagnosed with invasive breast cancer later on in their lives, even though the DCIS would have been treated appropriately at the time. (aihw.gov.au)
  • Ductal carcinoma in situ (DCIS) of the male breast is very rare and has hardly been studied molecularly. (eur.nl)
  • In males, we compared methylation status of 25 breast cancer-related genes in pure DCIS (n = 18) and invasive breast carcinoma (IBC) with adjacent DCIS (DCIS-AIC) (n = 44) using methylation-specific multiplex ligation-dependent probe amplification. (eur.nl)
  • Since there was little change in the methylation status for the studied genes from pure male DCIS to DCIS-AIC and IBC, methylation of these seven genes is more likely to occur early in male breast carcinogenesis. (eur.nl)
  • Based on the current markers male DCIS seems to be an epigenetically more advanced precursor of male BC, although in comparison to its female counterpart it appears that fewer loci harbor methylation, pointing to differences between male and female breast carcinogenesis with regard to the studied loci. (eur.nl)
  • The use of a radiotherapy (RT) boost to the tumor bed after whole-breast RT (WBRT) for ductal carcinoma in situ (DCIS) is largely extrapolated from invasive cancer data, but robust evidence specific to DCIS is lacking. (ovid.com)
  • To compare ipsilateral breast tumor recurrence (IBTR) in women with DCIS treated with vs without the RT boost after breast-conserving surgery and WBRT. (ovid.com)
  • All patients had newly diagnosed pure DCIS (no microinvasion), underwent breast-conserving surgery, and received WBRT with or without the boost with a minimum of 5 years of follow-up required for inclusion in the analysis. (ovid.com)
  • This patient-level analysis suggests that the RT boost confers a statistically significant benefit in decreasing IBTR across all DCIS age groups, similar to that seen in patients with invasive breast cancer. (ovid.com)
  • AIM: The traditional architecture based classification system of ductal carcinoma in situ (DCIS) has been criticised on the grounds that individual lesions often show more than one pattern resulting in a large mixed category. (bmj.com)
  • Ductal carcinoma in situ (DCIS) is a frequent disease, concerning more than 15% of all breast carcinomas in France. (knowcancer.com)
  • MRI is not commonly performed today in the preoperative staging of DCIS, despite interesting results of breast MRI in DCIS evaluation published recently in a German study (Kuhl, Lancet 2007). (knowcancer.com)
  • The present study investigates the relationship between the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) between primary ductal carcinoma in situ (DCIS) and intra-individually matched ipsilateral event. (lu.se)
  • Ductal Carcinoma in Situ, also known as DCIS, is a pathological abnormality that is commonly found after a breast biopsy has been performed. (nhbcc.org)
  • Often misunderstood, DCIS is not an invasive breast cancer. (nhbcc.org)
  • Ductal carcinoma in situ (DCIS): are we overtreating it? (biomedcentral.com)
  • DCIS continues to increase in incidence as the number of women invited to population breast screening programmes increases. (biomedcentral.com)
  • As the numbers of patients with DCIS increases, so the number of women being treated by breast-conserving surgery and mastectomy increases. (biomedcentral.com)
  • Ductal carcinoma in situ (DCIS) is a common type of breast cancer that does not spread, but can mutate over time to become metastatic cancer. (brightsurf.com)
  • Both the study and the story involved patients with DCIS (ductal carcinoma-in-situ), the earliest form of breast cancer. (womensvoicesforchange.org)
  • Because there have been so many advances in the care and treatment of breast cancer in general, not just DCIS, there are more options than ever before. (womensvoicesforchange.org)
  • For example, often women who have large areas of DCIS in their breasts that would be difficult to remove in a small operation are advised to undergo mastectomy. (womensvoicesforchange.org)
  • We studied all cases of DCIS diagnosed through the Ontario Breast Screening Program from 1991 to 2000. (arctichealth.org)
  • Breast-conserving surgery (BCS) is an effective treatment for ductal carcinoma in situ (DCIS) but women who undergo BCS remain at risk for recurrences. (pubmedcentralcanada.ca)
  • The rates of diagnosis of ductal carcinoma in situ (DCIS), a localized precursor to invasive breast cancer, have been increasing over the past several decades. (pubmedcentralcanada.ca)
  • In 2007, more than 60,000 new cases of DCIS were estimated in the United States-accounting for approximately 25% of all breast cancer diagnoses. (pubmedcentralcanada.ca)
  • In the 1990s, trials demonstrated that breast-conserving surgery (BCS) is an appropriate treatment strategy for most women with DCIS. (pubmedcentralcanada.ca)
  • up to 20% of women with DCIS will have a recurrence within 5 years and approximately 50% of recurrences will be invasive breast cancer. (pubmedcentralcanada.ca)
  • 3 - 5 Further, women with DCIS are at a two to four-fold higher risk of developing cancer in the contralateral breast than women without prior DCIS. (pubmedcentralcanada.ca)
  • 7 , 8 Because recurrences after DCIS most commonly occur in the ipsilateral breast, mammographic surveillance for recurrences is important. (pubmedcentralcanada.ca)
  • Radiotherapy for ductal carcinoma (DCIS) is increasing, but the risks and benefits of the treatment remain uncertain. (springermedizin.de)
  • We aimed to investigate the relationship between radiotherapy for DCIS and risk of second non-breast cancers in a large US cohort. (springermedizin.de)
  • The estimated cumulative excess risk of all second non-breast cancers was 0.8% by 15 years after DCIS diagnosis. (springermedizin.de)
  • Groen EJ, Elshof LE, Visser LL, Rutgers EJT, Winter-Warnars HAO, Lips EH, Wesseling J (2016) Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS). (springermedizin.de)
  • We aimed to assess contralateral breast cancer (CBC) risk in patients with ductal carcinoma in situ (DCIS) compared with invasive breast cancer (BC). (eur.nl)
  • By utilizing two unique in vivo models of human non-invasive to invasive breast cancers, tandem ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) and mouse-intraductal models, we have shown for the first time that BCL9 may be an important molecular switch in the malignant transition of at least a subset of non-invasive cancers by enhancing canonical WNT signaling and promotion of epithelial-mesenchymal transition (EMT). (ku.edu)
  • Ductal carcinoma in situ (DCIS) of the breast : the need for psycho-social research. (lancs.ac.uk)
  • Since the introduction of the National Health Service Breast Screening Programme (NHSBSP), the number of ductal carcinoma in situ (DCIS) cases has increased considerably. (lancs.ac.uk)
  • The psychological issues that women with screen-detected DCIS have to deal with are different from those affecting women diagnosed with symptomatic breast cancer, and a summary of these issues is given. (lancs.ac.uk)
  • We report a rare case of synchronous bilateral and multifocal ductal carcinoma in situ (DCIS) in a 30-year-old patient operated on for gynecomastia following repeated injections of stanozolol, a non-aromatizable androgen. (uzh.ch)
  • PURPOSE: To identify breast MR imaging biomarkers to predict histologic grade and receptor status of ductal carcinoma in situ (DCIS). (harvard.edu)
  • We studied the effect of postoperative radiotherapy (RT) after breast sector resection for ductal carcinoma in situ (DCIS). (diva-portal.org)
  • Women undergoing sector resection for DCIS under conditions of population based screening mammography benefit from postoperative RT to the breast. (diva-portal.org)
  • Although it has been previously reported that radiotherapy (RT) effectively reduced the incidence of local recurrence of ductal carcinoma in situ (DCIS) following breast-conserving surgery (BCS), little is known about the effect of RT on survival of patients with locally excised DCIS. (oncologynurseadvisor.com)
  • Ductal carcinoma in situ (DCIS) is defined as a premalignant condition that involves proliferation of neoplastic mammary ductal epithelial cells without evidence of invasion beyond the basement membrane. (oncologynurseadvisor.com)
  • However, with the introduction of breast-conserving surgery (BCS) for the treatment of early-stage breast cancer, local excision of DCIS began to be widely adopted. (oncologynurseadvisor.com)
  • About 1 million women in the United States have been diagnosed with a condition called ductal carcinoma in situ, or DCIS. (pcori.org)
  • In DCIS, abnormal cells are found inside milk ducts in the breast. (pcori.org)
  • Having DCIS increases a woman's risk of getting a second diagnosis of DCIS or cancer in either breast. (pcori.org)
  • Patients must decide if keeping their breast is worth the higher risk of getting DCIS again or cancer. (pcori.org)
  • Next, the research team updated a computer model to predict the chances of survival, getting another DCIS, or getting breast cancer in the other breast. (pcori.org)
  • Correlation of histopathologic features of ductal carcinoma in situ of the breast with the oncotype DX DCIS score. (nextbio.com)
  • We wish to add a reference to the list included in the paper of Selim and colleagues 1 concerning androgen receptors in ductal carcinoma in situ (DCIS) of the breast that appeared in the Journal of Clinical Pathology in the first issue of 2002. (bmj.com)
  • In this study, cases of fibroadenoma, ductal carcinoma in situ (DCIS), and invasive mammary carcinoma were included. (bmj.com)
  • The role of HER2 in ductal breast carcinoma in situ (DCIS) is debated and recent data have suggested that HER2 is mainly related to in situ recurrences. (diva-portal.org)
  • Here, we demonstrate that HER2 positive disease in the primary DCIS is associated with lower risk of recurrent invasive breast cancer. (diva-portal.org)
  • PURPOSE: To evaluate survival and prognostic factors of 108 patients with clinically or mammographically detected ductal carcinoma in situ (DCIS), treated from 1980 to 1996 by complete local excision followed by external irradiation. (inserm.fr)
  • three patients had local recurrence of DCIS and six patients developed invasive breast cancer. (inserm.fr)
  • January 21, 2010 The term carcinoma in the phrase ductal carcinoma in situ (DCIS) is misleading and troubling and ought to be dropped, or at least its dropping should be considered, suggest some recent editorials in major journals. (curezone.org)
  • The prospect of changing terminology and treatment options in DCIS is complicated in the United States by what 2 different experts described as "hysteria" surrounding breast cancer. (curezone.org)
  • RESULTS: BAFF was ubiquitely expressed in breast carcinoma cells, DCIS, normal-appearing glands and ducts and peritumoral adipocytes. (inserm.fr)
  • DCIS is most often discovered during a mammogram used to screen for breast cancer. (mayoclinic.org)
  • To summarize data on long-term ipsilateral local recurrence (LR) and breast cancer death rate (BCDR) for patients with ductal carcinoma in situ (DCIS) who received different treatments. (biomedcentral.com)
  • Ductal carcinoma in situ (DCIS) of the breast is more commonly diagnosed as a result of population-based screening [ 1 ]. (biomedcentral.com)
  • We performed a systematic review, meta-analysis and meta-regression, focusing on studies with long-term outcomes (≥10 years) for DCIS categorized by the extent of local intervention ± tamoxifen (TAM) to assess LR and breast cancer death. (biomedcentral.com)
  • For this purpose, the p53 content of 100 human breast biopsies classified as ductal carcinoma (DCIS), was evaluated by immunohistochemical method. (ac.ir)
  • Preliminary data indicated that the presence of immunopositive p53 may be a valid predictive indicator of the prognosis of individuals with DCIS and transformation to invasive breast cancer. (ac.ir)
  • The cancer may form from the precancerous lesion called ductal carcinoma in situ. (wikipedia.org)
  • Impact of Margin Status on Local Recurrence after Mastectomy for Ductal Carcinoma in Situ," International Journal of Radiation Oncology * Biology * Physics, Vol. 85, No. 4, 2013, pp. (scirp.org)
  • Finally, the researchers performed meta-analyses on all factors associated with the recurrence of invasive breast cancer reported by more than one of these 17 high-quality studies and calculated the average effect size for each factor. (aacr.org)
  • Risk of recurrence after ductal carcinoma in situ of the breast. (aacrjournals.org)
  • This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). (centerwatch.com)
  • This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. (centerwatch.com)
  • Nevertheless, preoperative breast MRI has not been significantly associated with improvement in oncologic outcomes, such as lower recurrence rates or mortality. (ahrq.gov)
  • Ipsilateral breast tumor recurrence. (ovid.com)
  • Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G. (brightsurf.com)
  • 1 Approximately half of breast cancer deaths occurred without development of in-breast invasive recurrence. (ascopost.com)
  • Breast cancer mortality was not reduced with the prevention of ipsilateral invasive recurrence by the addition of radiotherapy to lumpectomy or with unilateral mastectomy vs lumpectomy. (ascopost.com)
  • Among 42,250 women who received lumpectomy and radiotherapy, 547 (1.3%) developed ipsilateral invasive recurrence and 163 (0.4%) died from breast cancer. (ascopost.com)
  • Among 19,762 women who received lumpectomy without radiotherapy, 595 (3.0%) developed ipsilateral invasive recurrence, and 102 (0.5%) died from breast cancer. (ascopost.com)
  • Among 25,527 who received unilateral or bilateral mastectomy, 200 (0.8%) had ipsilateral invasive recurrence and 154 (0.6%) died from breast cancer. (ascopost.com)
  • Among all patients, estimated 20-year risks were 5.9% for ipsilateral invasive recurrence and 6.2% for contralateral invasive recurrence, with estimated risks of 9.5% among patients with breast-conserving surgery without radiotherapy and 4.5% among those with breast-conserving surgery with radiotherapy. (ascopost.com)
  • 001) but not after ductal carcinoma in situ ipsilateral or contralateral recurrence. (ascopost.com)
  • of them, 517 (54%) did not develop in-breast invasive recurrence and 395 (41%) developed ipsilateral (n = 210) or contralateral (n = 165) invasive recurrence. (ascopost.com)
  • No in-breast invasive recurrence before death was observed in 94 (58%) of 163 who received lumpectomy and radiotherapy, 51 (50%) of 102 who received lumpectomy without radiotherapy, and 112 (73%) of 154 who received unilateral or bilateral mastectomy. (ascopost.com)
  • Previous research has shown that radiotherapy decreases the incidence of local recurrence after breast-conserving surgery in patients with ductal carcinoma in situ, but there was limited evidence demonstrating the impact of radiotherapy on survival, both overall and breast cancer-specific, in patients with locally excised ductal carcinoma in situ. (oncologynurseadvisor.com)
  • Multivariable analyses showed that independent predictors of ductal carcinoma in situ recurrence were low TXNIP expression (p=0.005, HR=0.51 and 95%CI: 0.32-0.81), larger ductal carcinoma in situ size and high nuclear grade. (nottingham.ac.uk)
  • TXNIP functions as a tumor suppressor gene with loss of its expression associated with ductal carcinoma in situ recurrence. (nottingham.ac.uk)
  • Our earlier meta-analysis yielded summary ipsilateral local recurrence (LR)-rates of 22.5 % for breast-conserving surgery (BCS), 8.9 % for BCS and radiotherapy (RT), and 1.4 % for mastectomy (Mx), with average follow-ups of 68, 62 and 80 months, respectively [ 2 ]. (biomedcentral.com)
  • Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. (greenmedinfo.com)
  • There's either no sign of a tumor in the breast or there is, but it's 20 mm or smaller (T0 or T1, N1, M0). (webmd.com)
  • There's no sign of a tumor in the breast. (webmd.com)
  • Ai L, Kim WJ, Kim TY, Fields CR, Massoll NA, Robertson KD, Brown KD (2006) Epigenetic silencing of the tumor suppressor cystatin m occurs during breast cancer progression. (springer.com)
  • Their unique cellular makeup makes treatment more difficult, while a low number of tumor cells in the breast milk ducts make the cells harder to spot due to their scarcity. (news-medical.net)
  • This study clearly demonstrated that type 4 invasive ductal carcinomas having fibrotic foci and atypical tumor-stromal fibroblasts within the fibrotic foci are significant outcome predictors for lymph node-negative and lymph node-positive, the pathologic UICC-TNM stage II and III, luminal A-subtype, luminal B-subtype, and equivocal HER2 subtype invasive ductal carcinoma patients. (nih.gov)
  • Lymph vessel tumor embolus grades 2 and 3 were significant outcome predictors for lymph node-positive, UICC pTNM stages II and III, luminal A-subtype, and triple-negative invasive ductal carcinoma patients (except lymph vessel tumor embolus grade 2 in luminal A-subtype patients). (nih.gov)
  • Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells. (clinicaltrials.gov)
  • Lumpectomy refers to the surgical removal of a cancerous lump (or tumor) in the breast along with a small margin of the surrounding normal breast tissue. (imaginis.com)
  • Tumor grade is an established indicator of breast cancer outcome, although considerable heterogeneity exists even within-grade. (aacrjournals.org)
  • BCL9 has been shown to promote tumor metastasis in multiple myeloma and colon carcinoma. (ku.edu)
  • While the histological tumor type itself (ductal versus lobular) did not influence the lymph node status, multifocal and diffuse distribution of the lesions were associated with significantly increased risk of lymph node metastases in both ductal and lobular cancers. (diva-portal.org)
  • Under the advice of the cancer clinic and because the margin of clear breast was small and the tissue surrounding the tumor contained many obvious abnormalities, the surgeon carried out a wider resection of the same area and excised the sentinal axillary node six months after I met her. (curezone.org)
  • Immunohistochemical examination revealed that the tumor cells tested positive for estrogen receptor and negative for progesterone receptor, which was consistent with primary breast cancer. (springermedizin.de)
  • The focus of this study was to determine if early detection of mutant p53 accumulation may be an early indicator of tumor aggressiveness and transformation to invasive breast cancer. (ac.ir)
  • Epstein-barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. (greenmedinfo.com)
  • In a study on in situ breast cancer no lymph node involvement was seen. (greenmedinfo.com)
  • Long-term statin use is associated with an increased risk of ductal and lobular breast cancer among women 55-74 years of age. (greenmedinfo.com)
  • Dear tmouse, The treatment of recurrent breast cancer varies depending on where the cancer has recurred. (medhelp.org)
  • A quick primer on the different ways breast cancer can be treated. (medhelp.org)
  • From mammograms to personal hygiene, learn the truth about these deadly breast cancer rumors. (medhelp.org)
  • Breast cancer is not an inevitability. (medhelp.org)
  • Where Breast Cancer Spreads: 5 most common places. (webmd.com)
  • Ductal carcinoma is a common type of breast cancer that starts in cells that line the milk ducts, which carry breast milk to the nipple. (webmd.com)
  • Staging is the name for the process doctors use to figure out if and how far breast cancer has spread. (webmd.com)
  • Invasive ductal carcinoma (IDC), also known as infiltrating ductal carcinoma, is cancer that began growing in a milk duct and has invaded the fibrous or fatty tissue of the breast outside of the duct. (hopkinsmedicine.org)
  • IDC is the most common form of breast cancer, representing 80 percent of all breast cancer diagnoses. (hopkinsmedicine.org)
  • As with any breast cancer, there may be no signs or symptoms. (hopkinsmedicine.org)
  • At the Johns Hopkins Breast Center, we know how quickly patients want results from a biopsy or scan if there is a suspicion of breast cancer. (hopkinsmedicine.org)
  • At Johns Hopkins Medicine, our team of breast cancer specialists is dedicated to developing cutting-edge techniques for surgery , breast reconstruction , chemotherapy , biologic targeted therapy , radiation therapy and other hormonal therapies . (hopkinsmedicine.org)
  • Our research allows us to make great strides forward for patients with breast cancer. (hopkinsmedicine.org)
  • Medullary Ductal Carcinoma - This type of cancer is rare and only three to five percent of breast cancers are diagnosed as medullary ductal carcinoma. (hopkinsmedicine.org)
  • Mucinous Ductal Carcinoma - This occurs when cancer cells within the breast produce mucous, which also contains breast cancer cells. (hopkinsmedicine.org)
  • Papillary Carcinoma - This is a very good prognosis breast cancer that primarily occur in women over the age of 60. (hopkinsmedicine.org)
  • Tubular Ductal Carcinoma - This is a rare diagnosis of IDC, making up only two percent of diagnoses of breast cancer. (hopkinsmedicine.org)
  • Tubular breast cancer has an excellent prognosis. (hopkinsmedicine.org)
  • Search breast cancer topics in the Johns Hopkins Health Library . (hopkinsmedicine.org)
  • Learn more about breast cancer research and treatment from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins-one of the world's premier cancer institutions. (hopkinsmedicine.org)
  • His sister died at age 58 of metastatic breast cancer and his father succumbed to complications from melanoma. (hindawi.com)
  • Additionally, he has a niece who was recently diagnosed with breast cancer. (hindawi.com)
  • Focused ultrasound of the right breast in the retroareolar region better demonstrates the biopsy-proven invasive breast cancer. (hindawi.com)
  • Generally, male breast cancer presents as an invasive carcinoma. (hindawi.com)
  • It is anticipated that new biologic agents, when combined with hormonal agents such as SERMs and aromatase inhibitors, may one day prevent all forms of breast cancer. (hindawi.com)
  • Also searched for Ductal breast carcinoma , Antimitotic , and Ductal breast cancer . (clinicaltrials.gov)
  • P. Gaye and A. Kassé, "Overview of Ductal Carcinoma in Situ of the Breast," Journal of Cancer Therapy , Vol. 5 No. 2, 2014, pp. 222-224. (scirp.org)
  • Detection of Ductal Carcinoma in Situ in Women Undergoing Screening Mammography," Journal of the National Cancer Institute, Vol. 94, No. 20, 2002, pp. 1546-1554. (scirp.org)
  • Tamoxifen in Treatment of Intraductal Breast Cancer: National Surgical Adjuvant Breast and Bowel Project B-24 Randomised Controlled Trial," Lancet, Vol. 353, No. 9169, 1999, pp. 1993-2000. (scirp.org)
  • The American Cancer Society estimates that more than 62,000 news cases of carcinoma in situ will be diagnosed this year. (imaginis.com)
  • Stage 0 breast cancer is a contained cancer that has not spread beyond the ductal system (to the lymph nodes or other areas of the body). (imaginis.com)
  • The presence of intraductal component in the infiltrating carcinoma seems to increase DFS and may be an independent and favorable prognostic factor for breast cancer. (springer.com)
  • Risk factors for breast cancer in women with proliferative breast disease. (springer.com)
  • The molecular journey from ductal carcinoma in situ to invasive breast cancer. (springer.com)
  • Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. (springer.com)
  • American Cancer Society (2007) American cancer society breast cancer facts and figures 2007-2008. (springer.com)
  • There is a certain amount of debate surrounding the exact definition of advanced breast cancer (ABC). (news-medical.net)
  • Forty studies met the eligibility criteria of including at least ten invasive breast cancer events and at least one year of follow-up. (aacr.org)
  • Breast cancer is the most important neoplasm in adult women, and its worldwide incidence is growing. (scielo.br)
  • Breast cancer is the most common malignancy among women almost throughout the whole world, and its incidence has been growing over recent decades. (scielo.br)
  • 1 Infiltrating ductal carcinoma (DC) is the most common form of breast cancer. (scielo.br)
  • Post-menopausal hormone therapy with estrogen plus progestin is consistently reported to be associated with an increased risk of invasive breast cancer. (healthpartners.com)
  • Invasive ductal breast cancer is the most common type of breast cancer in both women and men and accounts for about 75% of all breast cancers. (breastcancercare.org.uk)
  • Breast cancer not otherwise specified (NOS). (breastcancercare.org.uk)
  • It's sometimes referred to as 'no special type' or 'not otherwise specified' because the cells have no particular features that class them as a specific type of breast cancer when examined under the microscope. (breastcancercare.org.uk)
  • If you have any questions about breast cancer please contact the Helpline on 0808 800 6000. (breastcancercare.org.uk)
  • Using BRIM, micrographs of biomarkers whose expression correlates with breast cancer aggressiveness are divided by micrographs of biomarkers whose expression negatively correlates with aggressiveness to create computed micrographs reflecting aggressiveness. (nature.com)
  • This increase, however, was not accompanied by a commensurate reduction in the number of advanced breast cancer patients. (nature.com)
  • Written by experts in the field, Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer is a comprehensive, state-of-the art review of the field, and serves as a valuable resource for clinicians, surgeons and researchers with an interest in breast cancer. (waterstones.com)
  • Using Autopsy Series To Estimate the Disease "Reservoir" for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find? (annals.org)
  • Should This Woman With Dense Breasts Receive Supplemental Breast Cancer Screening? (annals.org)
  • Detection of multicentric breast cancer using dedicated breast PET. (annals.org)
  • Invasive micropapillary carcinoma (IMPC) of the breast and triple negative breast cancer (TNBC) are both aggressive subtypes, but little information is available on their comparison. (nih.gov)
  • Triple negative breast cancer. (nih.gov)
  • After treatment, there is still a small chance that cancer will return to the breast. (komen.org)
  • This phase II trial studies how well sirolimus works in preventing invasive breast cancer in patients with breast cancer confined to the mammary ducts or lobules of the breast. (cancer.gov)
  • This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. (clinicaltrials.gov)
  • Estrogen can cause the growth of breast cancer cells. (clinicaltrials.gov)
  • To compare post-therapy changes in symptoms as captured in the breast cancer prevention trial (BCPT) Eight Symptom Scale (BESS) questionnaire and skin reactions to 4-OHT gel. (clinicaltrials.gov)
  • This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer. (centerwatch.com)
  • Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. (centerwatch.com)
  • This study will help to show whether weight loss programs should be a part of breast cancer treatment. (centerwatch.com)
  • This randomized controlled trial of weight loss interventions in overweight and obese women with early stage breast cancer consists of two arms, please see the arms section for more information. (centerwatch.com)
  • Primary objective To compare the effect of a supervised weight loss intervention plus health education materials versus health education materials alone upon invasive disease free survival (IDFS) in overweight (BMI 27-29.9 kg/m2) and obese (BMI 30kg/m2) women diagnosed with HER-2 negative, stage II and III breast cancer. (centerwatch.com)
  • To determine the impact of a supervised weight loss intervention on IDFS within subgroups of women with 1) hormone receptor positive breast cancer and 2) hormone receptor negative breast cancer. (centerwatch.com)
  • To evaluate the change in endoxifen levels after an increase in tamoxifen citrate dose from 20 mg to 40 mg in women with breast cancer or ductal breast carcinoma in situ with intermediate-metabolizing CYP2D6 genotypes. (clinicaltrials.gov)
  • Breast Cancer Res Treat. (medifocus.com)
  • A Cox proportional hazard model was used to compare adjusted risk of breast cancer among women with high (BI-RADS 3 or 4) versus low (BI-RADS 1 or 2) breast density. (aacrjournals.org)
  • Results: During a median follow-up period of 39 months (0-132 months), 133 women developed invasive breast cancer. (aacrjournals.org)
  • Substantial evidence supports the hypothesis that breast cancer development occurs through a series of genomic and epigenomic alterations ( 4 , 8 ). (aacrjournals.org)
  • Our understanding of the factors that can affect the occurrence of subsequent invasive breast cancer remains limited. (aacrjournals.org)
  • Breast cancer incidence is three to six times higher among women with increased breast density compared with age-matched controls with low breast density ( 17 - 21 ). (aacrjournals.org)
  • In fact, breast density remains one of the strongest risk factors for invasive breast cancer, second only to deleterious germ line BRCA mutations. (aacrjournals.org)
  • Breast cancer is the second most frequent type of neoplasm among women, ( 1 ) representing approximately 22% of new cases diagnosed every year. (scielo.br)
  • Hospital-based and forensic autopsy series examining women not known to have had breast cancer during life. (annals.org)
  • The lipid-reactive oxygen species phenotype of breast cancer. (rsc.org)
  • The paper demonstrates that Raman imaging has reached a clinically relevant level in regard to breast cancer diagnosis applications. (rsc.org)
  • I was diagnosed for cancer a 2nd time on the same breast. (empowher.com)
  • The five most differentially targeted antigens were selected to generate an autoantibody signature for the in situ to invasive breast cancer transition. (aacrjournals.org)
  • This study shows the clinical relevance of a combination of 5 antigens, identified by protein microarrays and validated in an independent cohort of 120 samples by ELISA, as a blood-screening signature for the in situ to invasive breast cancer transition determination. (aacrjournals.org)
  • The serum markers currently used in clinical settings, including ACE and CA15-3, are mostly used to monitor treatment effectiveness in patients with metastatic breast cancer ( 4 ). (aacrjournals.org)
  • Pathological prognostic factors in breast cancer. (nii.ac.jp)
  • Conclusion: The findings of this study are comparable to results in the literature on OPS and demonstrate that OPS is an attractive alternative to standard lumpectomy for Canadian general surgeons who treat breast cancer. (medworm.com)
  • This study compared the prevalence of breast and other cancers in women with monoallelic and biallelicCHEK2 PVs.MethodsCHEK2 PV carriers were identified through commercial hereditary cancer panel testing (09/2013 -07/2019). (medworm.com)
  • MRI use varied across geographic areas and demographic characteristics, with higher use in urban areas and for younger women diagnosed with breast cancer. (ahrq.gov)
  • The American Cancer Society estimates that 229,060 new cases of invasive breast cancer were diagnosed and 39,920 people died of the disease in the United States in 2012. (ahrq.gov)
  • Magnetic resonance imaging (MRI) findings may lead to changes in treatment plans such as wider excisions, unilateral mastectomy, and/or early detection and treatment of contralateral breast cancer. (ahrq.gov)
  • Results were compared to female breast cancer (BC). (eur.nl)
  • Robust characterization of this basal group is necessary if it is to have a major impact on management of patients with breast cancer. (aacrjournals.org)
  • Breast cancer is a heterogeneous disease with a disparate variety of histological types and a wide spectrum of responsiveness to different treatments, making clinical management difficult. (aacrjournals.org)
  • Background: Emerging data propose biomarker alteration due to clonal selection between the primary invasive breast cancer and corresponding metastases. (lu.se)
  • Of the 274 patients who developed a local relapse, 135 developed a new in situ carcinoma and 139 an invasive cancer up to 31st December 2011. (lu.se)
  • Breast cancer is the most common cancer in the UK and is responsible for thousands of deaths each year. (brightsurf.com)
  • The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer. (brightsurf.com)
  • New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone. (brightsurf.com)
  • A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells. (brightsurf.com)
  • A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy. (brightsurf.com)
  • Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic. (brightsurf.com)
  • A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue. (brightsurf.com)
  • Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery. (brightsurf.com)
  • A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery. (brightsurf.com)
  • The breast cancer cure rate is at an all-time high, and so is the information - and misinformation - available to patients and their families. (womensvoicesforchange.org)
  • In her book, The New Generation Breast Cancer Book: How to Navigate Your Diagnosis and Treatment Options-and Remain Optimistic-in an Age of Information Overload , she describes every possible test and every type of doctor visit, providing a comprehensive, empathetic guide that a newly diagnosed woman (and her family) will want to have at her side. (womensvoicesforchange.org)
  • Whenever big news in breast cancer is reported, those of us who are in the thick of it, the physicians actually taking care of women with breast cancer, brace ourselves for the flurry of phone calls, emails and texts from our patients wanting to know one thing: "How does this new development apply to me? (womensvoicesforchange.org)
  • As a result there is no place anymore for the "one size fits all" approach in taking care of women with breast cancer. (womensvoicesforchange.org)
  • Some of the factors that contribute to decision making about treatment on an individual basis include: age, overall health status, the amount of cancer in the breast, whether or not there is a concern for spread, and of course, what does the patient herself want? (womensvoicesforchange.org)
  • 2 Before the 1980s, virtually all women with breast cancer, in situ as well as invasive, were treated with mastectomy. (pubmedcentralcanada.ca)
  • In breast cancer, the presence of p53 gene alterations has been associated with worse prognosis. (thescipub.com)
  • We support that mutation in p53 gene can be exploited as a prognostic marker for the early diagnosis of breast cancer, although more clinical and epidemiological data is required to establish this claim. (thescipub.com)
  • Breast Cancer Research and Treatment, 97(2):173-176. (uzh.ch)
  • The familial medical history was negative for breast cancer and work-up of serum hormone levels was normal. (uzh.ch)
  • Secondary endpoints were contralateral breast cancer, distant metastasis and death. (diva-portal.org)
  • The outcome of breast cancer mortality for [ductal carcinoma in situ] patients is of importance in itself and potential treatments that affect mortality are deserving of study. (ascopost.com)
  • In a study reported in JAMA Oncology , Steven A. Narod, MD, FRCPC , of Women's College Research Institute, Women's College Hospital, and the University of Toronto, and colleagues found that the risk of breast cancer mortality was elevated in patients with ductal carcinoma in situ compared with the general population, with risk being higher among younger vs older women and black vs white women. (ascopost.com)
  • and 7.1% had a second primary breast cancer. (ascopost.com)
  • At 20 years, overall breast cancer-specific mortality was 3.3% (95% confidence interval [CI] = 3.0%-3.6%), with risk being 1.8 times higher vs the general population (standardized mortality ratio = 1.8, 95% CI = 1.7-1.9). (ascopost.com)
  • Breast cancer tissue array (mostly ductal carcinoma in situ), including pathology grade, TNM, cli. (lucerna-chem.ch)
  • It was estimated that in screening units with a ductal carcinoma in situ detection rate of 1.00 to 2.22/1,000 women, every 3 cases of ductal carcinoma in situ was associated with 1 fewer invasive interval cancer in the next 3 years. (ascopost.com)
  • In a UK retrospective population-based study reported in The Lancet Oncology , Duffy et al found a significant inverse association between the detection of ductal carcinoma in situ in breast cancer screening and the incidence of invasive interval cancers diagnosed within 3 years after screening. (ascopost.com)
  • 1.5/1,000 women, it was estimated that 1 invasive cancer was avoided for every 6 ductal carcinoma in situ cases. (ascopost.com)
  • in these units, for every 3 cases of ductal carcinoma in situ, there was 1 less invasive interval cancer. (ascopost.com)
  • Radiotherapy improves overall survival in women with locally excised ductal carcinoma in situ, and improves breast cancer-specific survival particularly in estrogen receptor (ER)-negative/borderline and younger patients, according to an analysis published in the journal OncoTargets and Therapy . (oncologynurseadvisor.com)
  • however, after stratifying by ER status and age, researchers found that radiotherapy was beneficial for improving breast cancer-specific survival in ER-negative patients and patients under 50 years of age. (oncologynurseadvisor.com)
  • Overall survival (OS) and breast cancer-specific survival (BCSS) were compared among patients who received RT or no RT using the Kaplan-Meier methods and Cox proportional hazards regression models. (oncologynurseadvisor.com)
  • Correlation of estrogen, progesterone and androgen receptors in breast cancer. (bmj.com)
  • Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. (bmj.com)
  • Background: HER2 is a well-established prognostic and predictive factor in invasive breast cancer. (diva-portal.org)
  • HER2 status in relation to new ipsilateral events (IBE) and Invasive Breast Cancer Recurrences, local or distant (IBCR) was assessed by Kaplan-Meier survival analyses and Cox proportional hazards regression models. (diva-portal.org)
  • Eighteen women died from breast cancer and another 114 had died from other causes. (diva-portal.org)
  • Familiy history of breast cancer, sister at the age of 59. (radiopaedia.org)
  • Lack of Iodine causes fibrocystic disease, so women who have fibrocystic disease are susceptible to breast cancer. (curezone.org)
  • Not only was there a ductal carcinoma with multiple foci up to 5 cms from the main lesion, but tissues surrounding her cancer contained many abnormal breast changes including carcinoma in situ.The margins of the cancer came within 0.5 mm of the resection margin. (curezone.org)
  • When a wider resection was carried out all resected breast tissue was completely clear of fibrocystic disease, pre-cancerous and cancer lesions. (curezone.org)
  • The pathology of lobular carcinoma in situ in a male as well as screening MRI surveillance of male patients at high risk for breast cancer are discussed, emphasizing the importance of screening and imaging follow up in men who are at high risk for breast cancer. (jcancer.org)
  • HER2 is an established negative prognostic factor in invasive breast cancer [ 11 ]. (biomedcentral.com)
  • An approximation of the gene expression based subtypes using immunohistochemical (IHC) detection of HER2, estrogen receptor- (ER) and progesterone receptor (PR) expression has been suggested for invasive breast cancer [ 20 ]. (biomedcentral.com)
  • Gallbladder metastasis from breast cancer, especially from ductal carcinoma, is rare. (springermedizin.de)
  • A 78-year-old woman presented with right upper abdominal tenderness and positive Murphy's sign during chemotherapy for advanced multiple metastases of the breast cancer. (springermedizin.de)
  • In conclusion, gallbladder metastasis should be considered in patients with multiple metastatic breast cancer who present with signs or symptoms of cholecystitis. (springermedizin.de)
  • Inflammatory metastatic breast cancer with gallbladder metastasis: an incidental finding. (springermedizin.de)
  • Acute acalculous cholecystitis due to breast cancer metastasis to the cystic duct. (springermedizin.de)
  • Gallbladder metastases of breast cancer: from clinical-pathological patterns to diagnostic and therapeutic strategy. (springermedizin.de)
  • Background: Medullary breast carcinoma (MBC) is a unique histological subtype of breast cancer. (ac.ir)
  • Thus it might be a link between obesity and breast cancer. (scitechnol.com)
  • In this project we tried to study causative association of obesity and serum leptin with invasive ductal breast cancer (IDC) in a sample of Malaysian population. (scitechnol.com)
  • Since high serum leptin in IDC patients persists unabated in the post-operative state, we infer that the source of leptin in these cases cannot be the breast cancer tissue itself and leptin cannot be a marker for breast cancer. (scitechnol.com)
  • Highly significant association between serum leptin and IDC patients suggests that leptin in serum might play a causative role in the tumorigenesis of breast cancer, and it might be an important connection between obesity and breast cancer. (scitechnol.com)
  • Expression of TNF-superfamily members BAFF and APRIL in breast cancer: Immunohistochemical study in 52 invasive ductal breast carcinomas. (inserm.fr)
  • METHODS: We have assayed by immunohistochemistry 52 human breast cancer biopsies for the expression of BAFF and APRIL and correlated our findings with clinicopathological data and the evolution of the disease. (inserm.fr)
  • CONCLUSIONS: Our data show, for the first time, an autocrine secretion of BAFF and APRIL from breast cancer cells, offering new perspectives for their role in neoplastic and normal breast cell biology and offering new perspectives for possible selective intervention in breast cancer. (inserm.fr)
  • They showed that CXCR4 is highly expressed in malignant breast cancer but not in normal breast tissue, and the ligand SDF-1 was highly expressed in bone marrow, lung and lymph nodes, where breast cancer cells metastasize preferentially. (biomedcentral.com)
  • Moreover, they demonstrated that neutralization with a specific monoclonal antibody against CXCR4 effectively inhibited the metastasis of breast cancer cells to the lung or lymph nodes in mice. (biomedcentral.com)
  • Invasive carcinoma of no special type (NST) is the most common form of invasive breast cancer. (wikipedia.org)
  • It accounts for 55% of breast cancer incidence upon diagnosis, according to statistics from the United States in 2004. (wikipedia.org)
  • Breast cancer (Infiltrating ductal carcinoma of the breast) assayed with anti HER-2 (ErbB2) antibody. (wikipedia.org)
  • Invasive ductal carcinoma, with occasional entrapped normal ducts (arrow) The appearance of cancer cells under a microscope is another predictor of systemic spread. (wikipedia.org)
  • On clinical and histological grounds, the diagnosis of an infiltrating ductal mamma carcinoma staged T4cN2aM0 with subsequent auto-amputation was made and chemotherapy was initiated. (scielo.org.za)
  • All subjects had an American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) breast density measure recorded prior to diagnosis. (aacrjournals.org)
  • Elisa Port, M.D., FACS, chief of breast surgery at The Mount Sinai Hospital and co-director of the Dubin Breast Center in Manhattan, offers a valuable perspective on how to approach reports of new developments on screening, diagnosis, prognosis and treatment. (womensvoicesforchange.org)
  • We estimated relative risks (RRs), attributable risks (AR), and excess absolute risks (EAR) of second non-breast cancers associated with radiotherapy using Poisson regression adjusted for age at year of diagnosis, grade, hormonal therapy (yes/no or unknown), and time since diagnosis. (springermedizin.de)
  • basically this is info that I feel important for anyone with FBD, also anyone with a diagnosis of ductal carcinoma in situ. (curezone.org)
  • Breast neoplasms. (scielo.br)
  • Once again, the presence of ETV6-NTRK3 seems to make these particular neoplasms behave more indolent than their aggressive Ductal Carcinoma counterparts, which do not harbor the ETV6-NTRK3 gene fusion. (atlasgeneticsoncology.org)
  • Lobular carcinoma in situ is a form of in situ neoplasia that develops within the terminal lobules of the breast. (jcancer.org)
  • The authors herein report an unusual case of incidentally discovered lobular carcinoma in situ in a male patient with recurrent bilateral gynecomastia who was subsequently diagnosed with invasive ductal carcinoma of the left breast. (jcancer.org)
  • When comedo type breast tumors are cut, the dead cells inside of them (necrosis) can be expressed out just like a comedo or blackhead on the skin. (imaginis.com)
  • Invasive lobular and ductal breast tumors have distinct histologies and clinical presentation. (aacrjournals.org)
  • Epithelial derived tumors, such as the breast carcinomas , arise from the Ectoderm. (atlasgeneticsoncology.org)
  • Histological Typing of Breast Tumors. (nii.ac.jp)
  • Around 25% of grade III invasive ductal breast carcinomas are associated with a "basal" phenotype, and these tumors are reported to be a distinct subgroup. (aacrjournals.org)
  • Although a comprehensive characterization and definition of basal tumors is lacking, there are a number of features reported to be associated with this phenotype of invasive ductal carcinoma-no special type. (aacrjournals.org)
  • When the distribution of the in situ and invasive component in the same tumors was combined to give an aggregate pattern, the ductal carcinomas were unifocal in 41.6% (244/586), multifocal in 31.6% (185/586), and diffuse in 26.8% (157/586) of the cases. (diva-portal.org)
  • Tissue microarrays from 776 pure ductal carcinoma in situ and 239 mixed ductal carcinoma in situ and invasive tumors were constructed. (nottingham.ac.uk)
  • Our aim was to evaluate and compare lymph node involvement, as well as disease-free survival (DFS) and overall survival (OS), between infiltrating ductal carcinoma with (group 1) and without (group 2) intraductal carcinoma component in order to determine the prognostic value of the intraductal component. (springer.com)
  • 99% of thetumor volume) (Figure 9) and minor components of poorly differentiated infiltrating ductal carcinoma, not otherwise specified (Elston Score = 8), and high-grade intraductal carcinoma, cribriform-type with apocrine features (Figure 10). (appliedradiology.com)
  • R. Whitfield, J. Kollias, P. de Silva, J. Turner and G. Maddern, "Management of Ductal Carcinoma in Situ according to Van Nuys Prognostic Index in Australia and New Zealand," ANZ Journal of Surgery, Vol. 82, No. 7-8, 2012, pp. 518-523. (scirp.org)
  • Prognostic classification of breast ductal carcinoma in situ. (springer.com)
  • Owing to the weakness of prognostic information given by cellular, biochemical and molecular features, instead of lymph node status, axillary dissection is still recommended in microinvasive ductal carcinoma in situ. (biomedsearch.com)
  • Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. (medworm.com)
  • TXNIP can be used as a potentially useful marker in prognostic stratification of ductal carcinoma in situ for management decisions. (nottingham.ac.uk)
  • The purpose of this study was to investigate the relationship between bcl-2 and p53 expression and to clarify their roles in apoptosis in different histological graded breast carcinomas. (nih.gov)
  • The majority of breast carcinomas fall into the category of invasive ductal carcinoma, no special type, for which histological grade is one of the best predictors of behavior. (aacrjournals.org)
  • A simple mastectomy (removal of the affected breast and often a small part of the underarm lymph nodes). (imaginis.com)
  • After a mastectomy , a woman may have immediate or delayed breast reconstruction. (imaginis.com)
  • Axillary lymph node involvement was found in 3 cases (i.e. 5%) which harbored poor histologic features: comedocarcinoma subtype, high nuclear grade, and size of the ductal carcinoma in situ greater than 3 cm, requiring total mastectomy. (biomedsearch.com)
  • The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. (medifocus.com)
  • Mastectomy is a surgical procedure involving the removal of the entire breast. (imaginis.com)
  • Radical mastectomy involves the removal of the affected breast, the pectoral chest muscles, all chest and underarm lymph nodes, and fat and skin from the chest. (imaginis.com)
  • For both groups, preoperative MRI use was higher for women treated with mastectomy than with breast-conserving surgery. (ahrq.gov)
  • Sometimes a patient and her doctor decide to have a mastectomy to remove the entire breast. (pcori.org)
  • Invasive ductal carcinoma (IDC) accounts for about 80% of all invasive breast cancers in women and 90% in men. (webmd.com)
  • Conclusions: Albeit rare, our results demonstrate that HER2 can be heterogeneously overexpressed and amplified in breast cancers, and this phenomenon appears to be more prevalent in ER-positive breast carcinomas. (aacrjournals.org)
  • With the increased availability of mammography, breast cancers are being detected earlier. (medifocus.com)
  • Ductal carcinoma in situ represents 10-15% of all new breast cancers diagnosed in the United States and accounts for 30-50% of cancers detected by screening mammography in women less than age 50 and 15-25% in women over age 50. (medifocus.com)
  • Minimally Invasive Intact Excision of High-Risk Breast Lesions and Small Breast Cancers: The Intact Percutaneous Excision (IPEX) Registry. (medifocus.com)
  • Thus these women warrant close medical surveillance in order to detect and treat any invasive breast cancers that may arise. (aihw.gov.au)
  • We have investigated whether this group of breast cancers has a distinguishing pattern of genetic alterations and which of these may relate to the different clinical outcome of these patients. (aacrjournals.org)
  • Radiotherapy was associated with an increased risk of all second non-breast cancers combined [RR 1.17, 95% confidence interval (CI) 1.08-1.28] and all in-field, radiation-related second cancers combined (RR 1.37, 95% CI 1.15-1.63), driven by second lung cancers (RR 1.33, 95% CI 1.10-1.60) and non-CLL leukemia (RR 1.71, 95% CI 1.02-2.86). (springermedizin.de)
  • Radiotherapy was associated with an increased risk of second non-breast cancers. (springermedizin.de)
  • Analysis of the TCGA database showed BCL9 to be highly amplified in many cancers including breast, bladder and liver. (ku.edu)
  • Furthermore, BCL9 was amplified in a significantly higher proportion of invasive basal breast cancers compared to other subtypes. (ku.edu)
  • We conclude that BCL9 plays a key role in the malignant transition of a subset of non-invasive breast cancers and may promote invasion through enhancement of canonical WNT, EGFR and STAT3 signaling. (ku.edu)
  • Screen detection of ductal carcinoma in situ was associated with a lower rate of invasive interval cancers, according to the findings of a UK retrospective population-based study. (ascopost.com)
  • However, estimates indicated that higher ductal carcinoma in situ detection rates were associated with diminishing returns in terms of invasive interval cancers avoided. (ascopost.com)
  • The rate of screen-detected ductal carcinoma in situ was inversely associated with the rate of invasive interval cancers (Poisson regression coefficient = -0.084, P = .002). (ascopost.com)
  • The investigators concluded: "The association between screen-detected ductal carcinoma in situ and subsequent invasive interval cancers suggests that detection and treatment of ductal carcinoma in situ is worthwhile in prevention of future invasive disease. (ascopost.com)
  • To compare the lesion distribution and the extent of the disease in ductal and lobular carcinomas of the breast, we studied 586 ductal and 133 lobular consecutive cancers. (diva-portal.org)
  • Ductal cancers were extensive in 45.7% (268/586), lobular in 65.4% (87/133) of the cases. (diva-portal.org)
  • The expression pattern of CXCR4 was significantly correlated with the degree of lymph node metastasis in breast cancers. (biomedcentral.com)
  • Biology and a treatment of ductal carcinoma in situ. (springer.com)
  • It begins in the cells of a milk duct, then it grows through the duct walls and into the surrounding breast tissue. (webmd.com)
  • rather it can feel like a spongy change of breast tissue. (hopkinsmedicine.org)
  • Breast conserving therapy (BCT), typically a lumpectomy (removal of the mass and a small margin of surrounding breast tissue) followed by radiation treatment . (imaginis.com)
  • 1,2 In one case, a malignant melanoma of the breast originating in the nipple was responsible for the gross tissue destruction, 1 the breast progressively atrophying and disintegrating to the point of disappearance. (scielo.org.za)
  • One can only speculate on the mechanism of auto-amputation of breast tissue as it has not been described. (scielo.org.za)
  • 4 It is reasonable to assume that auto-amputation of breast tissue is related to necrosis. (scielo.org.za)
  • V. To compare post-therapy breast tissue and plasma levels of estradiol and progesterone between arms (optional). (clinicaltrials.gov)
  • Breast tissue fragments obtained by incisional biopsy and surgical procedures of 37 women with ductal carcinoma in situ of the breast were subdivided into two groups: Group A, composed of women with low-grade ductal carcinoma in situ , and Group B, women with high-grade ductal carcinoma in situ . (scielo.br)
  • Vibrational signatures of human breast tissue (invasive ductal carcinoma and invasive lobular carcinoma) were used to identify, characterize and discriminate structures in normal (noncancerous) and cancerous tissues by confocal Raman imaging, Raman spectroscopy and IR spectroscopy. (rsc.org)
  • K-means clustering and basis analysis followed by PCA and PLSDA is employed to analyze Raman spectroscopic maps of human breast tissue and for a statistical analysis of the samples (82 patients, 164 samples). (rsc.org)
  • The surgeon makes a small incision over the breast lump, carefully excises (cuts free) the lump, and removes it from the breast along with at least 1 cm of surrounding tissue. (imaginis.com)
  • The extent of breast soreness correlates with the amount of tissue removed during surgery. (imaginis.com)
  • or alternatively, they leave a large amount of surrounding tissue to ensure breast reconstruction. (imaginis.com)
  • When Ductal Carcinoma in Situ is identified in a tissue sample, it is graded on a low, medium and high scale. (nhbcc.org)
  • Breast invasive ductal carcinoma tissue array, including TNM and pathology grade, 80 cases/80 cor. (lucerna-chem.ch)
  • Theoretically, we should have seen some pathology in her newly resected breast tissue. (curezone.org)
  • A sample of breast tissue in the area of concern is then removed with a needle. (mayoclinic.org)
  • During a core needle biopsy, a radiologist or surgeon uses a hollow needle to remove tissue samples from the suspicious area, sometimes guided by ultrasound (ultrasound-guided breast biopsy) or by X-ray (stereotactic breast biopsy). (mayoclinic.org)
  • The procedure allows you to keep as much of your breast as possible, and depending on the amount of tissue removed, usually eliminates the need for breast reconstruction. (mayoclinic.org)
  • While there is no need for axillary dissection in women with pure ductal carcinoma in situ, the management is quite different in proven microinvasion. (biomedsearch.com)
  • What is the prognosis for invasive ductal carcinoma? (hopkinsmedicine.org)
  • Pure mucinous ductal carcinoma carries a better prognosis than more common types of IDCs. (hopkinsmedicine.org)
  • Considered to be a subtype of infiltrating ductal carcinoma of the breast, but associated with a better prognosis. (atlasgeneticsoncology.org)
  • The younger population has a 100% survival rate at 5-years, whereas the adult population with SBC has a much poorer prognosis on par with infiltrating ductal carcinoma. (atlasgeneticsoncology.org)
  • Persistent S100A7 expression in invasive carcinoma is associated with a worse prognosis, and this effect may be mediated in part through interaction with the multifunctional cell signaling protein Jab1. (sigmaaldrich.com)
  • OBJECTIVE In this series of ductal carcinoma of the breast, immunoexpression of antimetastasis gene nm23 and tenascin was examined and the role in prognosis was investigated by correlation with the tumour grade and stage, and ER/PR immunoexpression. (semanticscholar.org)
  • Radiotherapy and Tamoxifen in Women with Completely Excised Ductal Carcinoma in Situ of the Breast in the UK, Australia, and New Zealand: Randomised Controlled Trial," Lancet, Vol. 362, No. 9378, 2003, pp. 95-102. (scirp.org)
  • Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery? (bmj.com)
  • SweDCIS : Radiotherapy after sector resection for ductal carcinoma in situ of the breast. (diva-portal.org)
  • The authors conclude that their findings need to be further validated in other databases before clinicians utilize them for decision-making and future studies should be conducted to identify patients with ductal carcinoma in situ and low-risk who may not benefit from radiotherapy. (oncologynurseadvisor.com)
  • Breast conserving surgery (BCS) was performed in 78.6 % of whom 44.0 % received postoperative radiotherapy. (diva-portal.org)
  • have described a short survival time in patients with schirrous carcinoma, and a positive correlation between desmoplastic reaction and lymph node metastasis. (scielo.br)
  • Left sentinel lymph node excisional biopsy revealed 2 lymph nodes without evidence of local metastatic carcinoma. (appliedradiology.com)
  • The role of axillary lymph node dissection for microinvasive ductal carcinoma in situ of the breast was analyzed in a series of 60 consecutive cases. (biomedsearch.com)
  • More than 5 mitotic figures in metastatic carcinoma to the lymph nodes was a significant outcome predictor for lymph node-positive, UICC pTNM stage II, and luminal A-subtype invasive ductal carcinoma patients. (nih.gov)
  • Ductal carcinoma in situ usually appears on mammography as an area of microcalcification (groups of small calcifications clustered together within the breast). (medifocus.com)
  • It is a multicentric, randomised study including patients from France presenting a unique, limited ( detected by mammography or breast ultrasound. (knowcancer.com)
  • In arm 1, a MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm from the initial lesion), not viewed on the mammography or breast ultrasound. (knowcancer.com)
  • In many cases, ductal carcinoma is asymptomatic, and detected as abnormal results on mammography. (wikipedia.org)
  • The pathology revealed grade 2-3 invasive ductal carcinoma of the right breast and ductal carcinoma in situ of the left breast. (hindawi.com)
  • Data from 389 cases of infiltrating ductal carcinoma of the breast were included in the study by means of reviewing medical charts and pathology slides. (springer.com)
  • Breast pathology. (springer.com)
  • Aims: HER2 gene amplification is observed in 9% to 15% of breast carcinomas. (aacrjournals.org)
  • In cases that were ER-positive, both the HER2-positive and HER2-negative components harboured alterations associated with ER-positive (luminal) carcinomas, such as gains of 1q+, losses of 16q, and amplifications of 8p12 and 11q13. (aacrjournals.org)
  • Loss/reduced cytoplasmic expression of TXNIP was associated with features of aggressiveness including high nuclear grade (p=1.6x10-5), presence of comedo necrosis (p=0.001) and oestrogen receptor negative (ER-)/HER2- ductal carcinoma in situ (p=4.6x10-5). (nottingham.ac.uk)
  • Immunohistochemical stains verified the metaplastic nature of this carcinoma. (appliedradiology.com)
  • Selim AA , Wells CA. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors. (bmj.com)
  • The expression of CXCR4 was evaluated by immunohistochemical study in 79 surgically resected invasive ductal carcinomas, and the relation between the staining pattern and clinicopathological features was examined. (biomedcentral.com)
  • In this study we therefore examined the expression of CXCR4 protein in surgically resected human ductal carcinomas by immunohistochemical staining, and analyzed whether the expression pattern of this chemokine receptor is correlated with metastatic potential and is predictive of clinical outcome in these patients. (biomedcentral.com)
  • Biopsy needle size is a factor associated with upstaging of ductal carcinoma in situ. (greenmedinfo.com)
  • The patient returned 3 days later for a stereotactic biopsy of the microcalcifications in the left breast and an ultrasound guided biopsy of the right breast mass. (hindawi.com)
  • A biopsy of the ulcer base demonstrated an infiltrating ductal carcinoma. (scielo.org.za)
  • Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified? (ovid.com)
  • During a stereotactic breast biopsy, your breast will be firmly compressed between two plates. (mayoclinic.org)
  • Here, a biopsy of a suspicious breast lump is being done. (mayoclinic.org)
  • If the area of concern needs further evaluation, the next step may be an ultrasound and a breast biopsy. (mayoclinic.org)
  • By 1975, the widespread use of this imaging technique not only resulted in early detection of lesions in the breast but also led to a 60-70% reduction in morbidity and mortality from malignant diseases of breast [ 2 ]. (hindawi.com)
  • Computerized classification of intraductal breast lesions using histopathological images. (springer.com)
  • Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. (springer.com)
  • Breast conservative treatment can be done for limited lesions. (knowcancer.com)
  • On physical examination, this lump usually feels much harder or firmer than benign breast lesions such as fibroadenoma. (wikipedia.org)
  • Morrow M, Van Zee KJ, Solin LJ, Houssami N, Chavez-MacGregor M, Harris JR, Horton J, Hwang S, Johnson PL, Marinovich ML et al (2016) Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. (springermedizin.de)
  • 2,3,5,7 This case of infiltrating ductal carcinoma with osseous metaplasia is unusual enough to not be definitely identified in any of these larger series. (appliedradiology.com)
  • 2,3,7 In contrast, the case reported by Evans et al 4 of infiltrating ductal carcinoma with osseous metaplasia is most analogous to ours, as their patient exhibited similar clinical features. (appliedradiology.com)
  • We feel that a study of AR CAG repeats in benign apocrine metaplasia, which is always immunohistochemically positive for AR, 5 together with and without cases of apocrine and/or non-apocrine in situ and invasive breast carcinoma, would be very valuable in highlighting the importance of CAG repeats and apocrine differentiation. (bmj.com)
  • Current clinicopathological parameters are useful predictors of breast ductal carcinoma in situ behaviour, but they are insufficient to define high risk patients for disease progression precisely. (nottingham.ac.uk)
  • Bankhead III A, Magnuson NS, Heckendorn RB (2007) Cellular automaton simulation examining progenitor heirarchy structure effects on mammary ductal carcinoma in situ. (springer.com)
  • In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Ductal Carcinoma in Situ of the Breast. (medifocus.com)
  • These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Ductal Carcinoma in Situ of the Breast. (medifocus.com)
  • We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Ductal Carcinoma in Situ of the Breast every 3 months. (medifocus.com)
  • We performed comparative genomic hybridization (CGH) analysis on 43 grade III invasive ductal breast carcinomas positive for basal cytokeratin 14, as well as 43 grade- and age-matched CK14-negative controls, all with up to 25 years (median, 7 years) of clinical follow-up. (aacrjournals.org)
  • ARM I: Patients apply afimoxifene gel to both breasts and receive placebo orally (PO) daily for 4-10 weeks in the absence of disease progression or unexpected toxicity. (clinicaltrials.gov)
  • My fibrocystic breast disease is just a memory now. (curezone.org)
  • Although breast scars from fluid leakage out of the cysts are often permanent, Iodine given therapeutically in the correct doses gradually gets rid of all fibrocystic disease except for the scars. (curezone.org)
  • The present review study incorporates 22 years of practical experience from a breast disease research center-based series of cases.Methods: Retrospectively, the medical records of 3,246 patients were reviewed in the Breast Disease Research Center, Shiraz University of Medical Science (Shiraz, Iran), from December 1993 to December 2015. (ac.ir)
  • Ductal" means "related to the milk ducts " and "in situ" means "in place. (komen.org)
  • A lumpectomy may be called a quandrantectomy when up to one fourth of the breast is surgically removed. (imaginis.com)
  • Lumpectomy is attractive to many women because it allows them to maintain most of their breast after surgery. (imaginis.com)
  • Because lumpectomy is intended to preserve the physical appearance of the breast, surgeons generally do not perform lumpectomy when over one fourth of the breast must be removed. (imaginis.com)
  • Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. (springer.com)
  • Tresserra F, Grasses PJ, Garrido M. Lesiones hiperplásicas y preinvasivas precursoras del cáncer de mama: desde la epiteliosis hasta la neoplasia ductal intraepitelial. (springer.com)
  • The role of synthetic androgens in the development of male breast neoplasia warrants further scrutiny. (uzh.ch)
  • Invasive ductal carcinoma-no special type, as determined morphologically, is thought to arise exclusively from the luminal epithelial cells of the breast. (aacrjournals.org)
  • Gallbladder metastases from ductal papillary carcinoma of the breast. (springermedizin.de)
  • Forty-four cases were subclinical mammographically-detected carcinomas revealed by the clusters of microcalcifications. (biomedsearch.com)
  • External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial. (medifocus.com)
  • 2,3,5,6 As studies of similar cases of metaplastic carcinoma by Gunhan-Bilgen et al 2 (n = 8), Velasco and colleagues 3 (n = 12), and Patterson and coworkers 7 (n = 9) found that patients usually present at approximately the age of 50 with a palpable breast mass. (appliedradiology.com)
  • All cases had an invasive ductal carcinoma that was graded in each case as grade 3. (springer.com)
  • The invasive component of ductal carcinomas was unifocal in 63.3% (371/586), multifocal in 35.5% (208/586), and diffuse in 1.2% (7/586) of the cases. (diva-portal.org)
  • In Kasami and colleague's study, none of the cases of invasive mammary carcinoma was tested for AR expression, but other studies 3, 4 have found that a subset of invasive breast carcinomas expresses AR. (bmj.com)
  • Histology of index secretory breast carcinoma (SBC) case demonstrating well-differentiated but invasive glands containing eosinophilic secretions. (atlasgeneticsoncology.org)
  • Histology showed invasive ductal carcinoma (no special type, NST). (radiopaedia.org)
  • The purpose of this study was to investigate the histologic factors that accurately predict patient outcome among 1042 patients with invasive ductal carcinoma of the breast. (nih.gov)
  • 8 mm was a significant outcome predictor for UICC pTNM stages I and III invasive ductal carcinoma patients. (nih.gov)
  • It also comprises approximately 7-10% of all breast biopsies. (medifocus.com)